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Prototoxin proteins have been identified as members of the Ly6/uPAR super family 
whose three-finger motif resembles that of α-bungarotoxin. Though they are known to 
modify the function of nAChRs, their specificity is still unclear. Our lab identified three 
prototoxin proteins in the chicken ciliary ganglion: Ch3ly, Ch5ly, and Ch6ly. Ch6ly was 
later identified as prostate stem cell antigen (PSCA), and specifically decreased the 
amount of calcium influx through the homomeric α7 nAChR subtype. I then identified 
Ch3ly and Ch5ly as LY6E and LYPD6B, respectively. I focused my attention on 
LYPD6B because of its expression in the brain. This dissertation tests whether LYPD6B 
is a prototoxin protein that specifically co-localizes with and modifies the function of the 
heteromeric α3β4* nAChRs (the other nAChR subtype expressed in the chicken ciliary 
ganglia). In the first part of my dissertation I performed intracellular two-electrode 
voltage clamp on Xenopus oocytes co-expressing human LYPD6B and different 
stoichiometries of the α3β4* nAChR, these included two (α3)2(β4)3 with 
β4−α3−β4−β4−α3 and β4−α3−β4−α3−β4 stoichiometries, two (α3)3(β4)2 with 
stoichiometries β4−α3−α3−β4−α3 and β4−α3−β4−α3−α3, two (α3β4)2(α5D) 
β4−α3−α5D−β4−α3 and β4−α3−β4−α3−α5D, and (α3β4)2(α5N) with stoichiometries 
β4−α3−α5N−β4−α3 and β4−α3−β4−α3−α5N. Concatemeric constructs are designed to 
link nAChR subunits, thus when translated it is done so as a single polypeptide. LYPD6B 
increased the acetylcholine (ACh) potency and desensitization rate, but decreased the 
maximum current response (Imax) for the (α3)3(β4)2 nAChR subtype. Yet, LYPD6B 
only decreased the Imax for the (α3β4)2α5 D-variant and not the N-variant (associated 
with increase nicotine consumption). For the second part of my dissertation, I determined 
if the expression of LYPD6B correlated with nAChRs in an activity dependent manner. 
Though LYPD6B mRNA expression correlates with nAChR subunit mRNA expression 
levels, it seemed to be independent of nAChR activity. To determine if fluorescent co-
localization occurs between LYPD6B and a specific nAChR subtype, I genetically 
engineered LYPD6B to express a human influenza hemagglutinin (HA) epitope tag and 
cloned into a chicken retrovirus. LYPD6B was shown to co-localize only with the α3β4* 
heteromeric and not the homomeric α7 nAChRs, in a nAChR activity dependent manner. 
This study adds to the complexity of a prototoxin’s function by suggesting that the 
specificity is dependent on nAChR type and stoichiometry. It is the first in identifying a 
prototoxin protein, LYPD6B, which specifically modulates the function of the 
(α3)3(β4)2 and (α3β4)2(α5 D-variant) heteromeric nAChR subtypes. For the (α3β4)2(α5 
D-variant) nAChR subtype LYPD6B decreased the Imax. Such observation may be 
telling of a novel mechanism involved with nicotine dependence. For the 
(α3)3(β4)2 nAChR subtype LYPD6B increases its ACh sensitivity, desensitization rate, 
while decreasing Imax. Additionally, the co-localization of LYPD6B and α3β4* nAChRs 
in the lack of nAChR activity highlights the relevance of the functional effects α3β4* 
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COMPREHENSIVE LITERATURE REVIEW 
 
I. Introduction 
In the simplest terms, the cholinergic system is defined by the cholinergic neurons that 
transmit and respond to action potentials, and the proteins involved in mediating such 
signals. The neurotransmitter within the brain that triggers a cholinergic synaptic 
response is acetylcholine (ACh; Albuquerque et al., 2009). The enzyme choline 
acetyltransferase synthesizes acetylcholine by transferring an acetyl group from acetyl-
CoA to choline (Albuquerque et al., 2009). The termination of a cholinergic response 
occurs with the breakdown of ACh into its two components by the enzyme 
acetylcholinesterase (Albuquerque et al., 2009). There are two types of receptors that are 
activated by ACh and mediate cholinergic signaling, muscarinic and nicotinic 
acetylcholine receptors (Albuquerque et al. 2009). The muscarinic acetylcholine 
receptors (mAChRs) are coupled to heterotrimeric guanine nucleotide-binding proteins 
(G proteins), which allow them to regulate second messenger activity (Eglen, 2006). 
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels (Albuquerque 
et al., 2009). Both receptor types are located pre- and postsynaptically with a discrete 
expression pattern both in the central and peripheral nervous system. Thus, the 
cholinergic system is known to be involved in an array of human behaviors. In our lab we 
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study the cholinergic system at the level of the nicotinic acetylcholine receptors 
(nAChRs).   
 
II. Nicotinic acetylcholine receptors (nAChRs) 
 
Nicotinic acetylcholine receptors (nAChRs) are a diverse group of ligand-gated ion 
channels. Based on evolutionary and physiological properties, nAChRs have been 
divided into three different categories (Le Novere and Changeux, 1995): 1) Skeletal 
muscle nAChRs, made up of α, β, γ, or ε subunits, 2) neuronal heteromeric nAChRs, 
made up of a combination of α2− α6 and β2− β4 subunits, and 3) neuronal homomeric 
nAChRs, made up of all α7, α8, α9, or α10 subunits. However, the α7 subunit has also 
been shown to form a receptor with the β2 subunit (Thomsen et al., 2015). All nAChRs 
are pentameric, composed of five subunits (Cooper et al., 1991). Each subunit has an 
extracellular NH2-terminal domain of about 200 amino acids, four transmembrane 
domains (TM), two intracellular loops (the second intracellular loop is located between 
the third and fourth TM and varies in size), and a relatively short extracellular COOH-
terminal (Albuquerque et al., 2009). Though certain nAChRs are more permeable to 
particular cations, in general the TM2 forms a hydrophilic non-selective cation pore 
(Albuquerque et al., 2009). The binding of the endogenous ligand ACh will activate the 
receptor, opening the pore, and allowing the flow of cations (Le Novere et al., 2002).  
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The ligand-binding site is a hydrophobic pocket formed between two neighboring 
subunits, the positive and negative face, which are defined by specific characteristics. A 
conserved property within the extracellular NH2-terminal towards TM1 is a cysteine-
cysteine pair separated by 13 amino acids, the pair forms a Cys-loop due to disulfide 
bonding (Karlin et al., 1986). This characteristic defines an α subunit, determines ligand-
binding site, and is termed as the positive face of a nAChR subunit (Lukas et al., 1999).  
Additionally, α subunits (with the exception of α5) express hydrophobic aromatic amino 
acids required for ligand binding (Karlin et al., 1986; Sine and Engel, 2006). The β 
subunit expresses three essential amino acids, leucine 112, methionine 114, and 
tryptopham in position 53, which are required for ligand recognition and is known as the 
negative face of a nAChR subunit (Sine and Engel, 2006). The α subunits that form 
homomeric nAChRs contain both positive and negative face characteristics (Albuquerque 
et al., 2009). 
 
Although neuronal heteromeric and homomeric nAChRs share common physiological 
features, the specific properties of each receptor state differ between the two nAChR 
subtypes. Both receptor subtypes may physiologically exist and spontaneously 
interchange among three different conformational states: resting (closed), active (open), 
and desensitized (closed) (Le Novere et al., 2002). A nAChR exists in the closed state in 
the absence of ligand. In a closed state there are two factors that do not allow the passage 
of cations. 1) The diameter of the pore and 2) The hydrophobic amino acids of all five 
TM2 domains, which face the pore of the receptor, thus acting as a barrier (Albuquerque 
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et al., 2009). A nAChR may enter the open state when a ligand such as ACh is bound. 
However, one characteristic that affects the ease of ligand binding is the receptor’s 
affinity towards that particular ligand. Studies have revealed that both the α and β 
subunits affect the potency of multiple agonists (Luetje and Patrick, 1991). Two-
electrode voltage clamp recordings, done on Xenopus oocytes injected with a 1:1 cRNA 
concentration ratio of human α2, α3, α4, β2, and β4 nAChR subunits, compared agonist 
potency by comparing the normalized partial dose-response curves of four agonists (ACh, 
nicotine, cytisine, and DMPP) for the α2β2, α2β4, α3β2, α3β4, α4β2, α4β4 nAChRs 
(Luetje and Patrick, 1991). For example, the nAChRs expressing a β4 subunit 
(α2β4, α3β4, α4β4) have a greater affinity to cytisine than the other agonists tested 
(Luetje and Patrick, 1991). Additionally, nAChRs have different sensitivities to 
antagonists, including α-bungarotoxin (Loring and Zigmond, 1988). Also, the ease of 
ligand binding is affected by the cooperative binding property. If the binding of a ligand 
to a receptor further increases the receptor’s affinity to the ligand, then this is termed as 
cooperative ligand binding and evident through the hill coefficient. A greater hill 
coefficient indicates positive cooperative binding and a smaller hill coefficient indicates 
less cooperative binding. The nAChRs that exhibit the greatest cooperative binding to 
ACh are as follows: α3β4, α2β4, homomeric α7, α4β4, α2β2, α3β2, and α4β2 (Elliott et 
al., 1996). When nAChRs enter the open state, cations flow across the membrane, as 
previously mentioned. When considering the open state of a nAChR, there are two 
channel properties that affect the cation flow: 1) the duration of open time and  
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2) conductance of the channel. In general nAChRs with varying α and β subunits exhibit 
a <0.1-8 ms open time duration with a conductance’s ranging from 5-45 ps (Role, 1992). 
In the presence of prolonged ligand exposure, nAChRs may transition from an open state 
to a desensitization state. The order of desensitization rates from fastest to slowest is as 
follows: homomeric α7, heteromeric α3β2, α4β2, α3β4, α2β2, α4β4, and α2β4 (Elliott 
et al., 1996). 
 
Nicotinic AChRs also express allosteric effector binding sites, which have the ability to 
modulate the properties of each physiological state. The binding of an effector to an 
allosteric binding site modifies the energy barriers between any two given physiological 
states (Bertrand and Gopalakrishnan, 2007). Positive allosteric modulators (PAM) lower 
the energy barrier between the closed and open state, and increase an open state response 
in the presence of agonist (Bertrand and Gopalakrishnan, 2007). Thus, there are two types 
of PAMs. Type I will increase the peak current response either by transiting the receptor 
into an open state at lower agonist concentrations (increasing agonist potency) or 
stabilizing the open state of the receptor in response to agonist (Bertrand and 
Gopalakrishnan, 2007). Type II will increase the peak current response and change the 
desensitization profile in response to agonist (Bertrand and Gopalakrishnan, 2007). 
Negative allosteric modulators (NAM) increase the energy barrier between the closed and 
open state, and decrease an open state response in the presence of agonist (Bertrand and 
Gopalakrishnan, 2007).      
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The expression of the different nAChR subtypes is regulated. The first step in regulating 
nAChR expression begins at the DNA level. Although there is not much evidence 
specifically identifying transcription factors that regulate the expression of nAChRs, 
there is some research investigating the α3/β4/α5 gene cluster and their coordinated 
expression. The CHRNA3/CHRNB4/CHRNA5 gene organization is located on 
chromosome 15q24 and will express α3/β4/α5 nAChR subunits respectively (Duga et al., 
2001). The CHRNA3 and CHRNB4 transcripts are transcribed in the same direction, 
whereas CHRNA5 is transcribed in the opposing direction (Duga et al., 2001). 
Furthermore, the 3’ tail end of the CHRNA5 transcript overlaps the 3’ tail end of the 
CHRNA3 transcript (Duga et al., 2001). The coordinated expression of the gene cluster is 
regulated by upstream promoter elements. Studying β43’ enhancer’s involvement in 
regulating the CHRNA3/CHRNB4/CHRNA5 gene cluster transcription followed its 
identification upstream of the 3’ end of the CHRNB4 transcript (McDonough and 
Deneris, 1997). By producing transgeneic mice that express a plasmid with a mutated 
β43’ enhancer, Xu et al. determined a decrease in the expression of CHRNA3, CHRNB4, 
and CHRNA5 transcripts (Xu et al., 2006). The group also identified conserved 
noncoding region 4 (CNR4) to regulate the expression of CHRNA3 and CHRNB4, but 
not CHRNA5 (Xu et al., 2006). Other evidence has also determined that the expression of 
CHRNA3 and CHRNB4 transcripts are regulated through the Ras-dependent MAPK 
pathway via NGF activation, and that the expression may be increased or decreased 
depending on the cell type (Nakayama et al., 2000). The second step in regulating the 
expression of nAChRs is the proper folding and assembly of the subunits, which occurs 
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in the endoplasmic reticulum. There is evidence identifying essential amino acids within 
the NH2 extracellular terminal, of the α7 and α3 nAChR subunits, in regulating proper 
subunit interactions for the formation of the functional homomeric α7 and heteromeric 
α3 nAChRs (Dunckley et al., 2003; Wanamaker et al., 2003). The third step in regulating 
the expression of nAChRs is at the level of embedding functional receptors into the 
plasma membrane. One way, cholinergic neurons regulate the appropriate folding and 
monitor glycosylation for proper nAChR plasma membrane insertion is through 
chaperone proteins. A well document endogenous nAChR chaperone protein is RIC3. By 
recording α7 nAChR currents, performing a co-immunoprecipitation, and quantifying 
radiolabeled alpha-bungarotoxin from α7 and RIC3 co-transfected human kidney tsA201 
cells, Lansdell et al. determined RIC3 to increase α7 nAChR expression and function, 
thus identifying RIC3 as an α7 nAChR chaperone protein (Lansdell et al., 2005). Yet, 
exogenous molecules also behave as chaperone proteins and upregulate the expression of 
nAChRs. An example of this is nicotine. Nicotine is not only known to upregulate the 
expression of the α4β2 nAChRs it is also believed to favor a higher nicotine affinity 
subtype, possibly by facilitating the formation of a specific α4β2 nAChR stoichiometry 
(Buisson and Bertrand, 2002; Moroni et al., 2006; Wonnacott, 1990). Though chaperone 
proteins have the ability to facilitate proper nAChR plasma membrane insertion, large 
amounts of evidence identify the majority of nAChRs to be kept in intracellular pools as 
opposed to being sent to lysosomes, and inserted into the plasma membrane, if conditions 
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permit (Fenster et al., 1999b; Jacob et al., 1986; Pakkanen et al., 2006; Whiteaker et al., 
1998).  
 
Where in the nervous system and at the neuronal cellular level the different nAChR 
subtypes are expressed has an impact on biological functions. The most abundantly 
expressed nAChRs, in the CNS, are the homomeric α7 and the heteromeric α4β2 
receptors (Couturier et al., 1990; Schoepfer et al., 1988). There are a few nuclei (e.g. 
medial habenula) within the brain that express distinct nAChRs; these include the α3β4 
and α3β4α5 (Scarr et al., 2013). The ventral tegmental area is known to have high levels 
of the α6 and β3 nAChR subunits (Scarr et al., 2013). In the CNS, nAChRs are expressed 
at presynaptic terminals, and modulate synaptic transmission by regulating the release of 
neurotransmitters. By radiolabeling the alpha-bungarotoxin and nicotine-binding sites, 
nAChRs at presynaptic terminals were identified within the interpeduncular nucleus and 
dopaminergic projections to striatum and accumbens (Clarke et al., 1986; Clarke et al., 
1987; Clarke and Pert, 1985). Additionally, studying synaptosome preparations revealed 
that presynaptic nAChRs regulate the release of norepinephrine, dopamine, GABA, 
serotonin, and ACh (el-Bizri and Clarke, 1994; King, 1990; Lapchak et al., 1989; Lena et 
al., 1993). Nicotinic AChRs at the postsynaptic level involved in mediating fast EPSPs in 
the CNS have been difficult to identify (Role and Berg, 1996). A reason for this might be 
the location of cholinergic projections, which are known to be deep within the limbic 
system (Role and Berg, 1996). Another, reason may be their implications in other 
functions besides fast EPSPs. In contrast to the CNS, the autonomic nervous system 
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abundantly expresses the α3 containing nAChRs; these include a combination of α3β4, 
α3β4α5, and sometimes α3β2 (Conroy and Berg, 1995; Vernallis et al., 1993). They are 
located postsynaptically and involved in mediating nicotinic transmission (Langley and 
Anderson, 1892). 
  
Non-traditional functions of nAChRs such as gene transcription, neuron survival, 
dendritic branching, and facilitating the reversal of the Cl- gradients, may be explained 
through their high permeability to Ca2+. Although nAChRs are considered non-selective 
cations, they can be more permeable to Ca2+ than Na+ and K+. This is particularly true for 
the α7 nAChR (Castro and Albuquerque, 1995). The α7 nAChR has the highest 
permeability to Ca2+ permeability of all nAChRs (Role and Berg, 1996). Additionally, the 
Ca2+ permeability is independent of membrane potential unlike the N-methyl-D-aspartic 
acid (NMDA) receptors, which are blocked by Mg2+ at resting membrane potentials 
(Role and Berg, 1996). The Ca2+ influx through nAChRs is known to switch on multiple 
cellular pathways. In differentiated PC12 cells, a 100µM nicotine exposure increased the 
mRNA levels of the c-fos transcription factor (Greenberg et al., 1986). Furthermore, 
when those cells were exposed to ethylene glycol tetraacetic acid (EGTA), a Ca2+ 
chelating agent, no increase in c-fos transcript was observed, thus the increase in c-fos via 
activation of nAChRs is Ca2+ dependent (Greenberg et al., 1986). Additionally, the influx 
of Ca2+ through activated nAChRs is known to activate protein kinase such as 
calmodulin-dependent protein kinase, phosphoinositide 3-kinase, protein kinase C, and 
protein kinase A (Albuquerque et al., 2009). In turn these kinases activate the 
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transcription factor, cAMP response element binding protein (CREB) (Albuquerque et 
al., 2009).  
 
III. The α5  nAChR subunit 
 
Structurally the α5 subunit resembles the other α nAChR subunits, but functionally it 
lacks a ligand-binding site. It is considered an α subunit because it contains the cysteine-
cysteine pair at the NH2- extracellular terminal (Albuquerque et al., 2009). However, a 
key polar ligand-binding amino acid, tyrosine, is replaced by the charged amino acid, 
aspartic acid (Albuquerque et al., 2009) so ACh cannot bind. Thus, in order for the α5 
subunit to form a functional nAChR, it must be incorporated into the pentamer in 
combination with other alpha subunits. There is evidence that α5 has the ability to form a 
nAChR with the α3, β4, and β2 subunits (Girod et al., 1999; Yu and Role, 1998). There 
is also evidence that α5 forms a receptor with the α7 subunit (Anand et al., 1993; Girod 
et al., 1999; Listerud et al., 1991).  
 
The α5 subunit is known as a modulator because channel properties are modified when it 
is incorporated into an nAChR pentamer. A larger conductance and low ACh affinity 
occurs in the heteromeric α3β4 and α3β2 nAChRs when combined with the α5 subunit 
(Yu and Role, 1998). Furthermore, the addition of the α5 subunit to nAChRs containing 
 11 
the α3 subunit causes a significant increase in calcium influx compared to the homomeric 
α7 nAChR (Yu and Role, 1998).  
 
The α5 nAChR subunit has an impact on human behavior. The α5 nAChR subunit was 
first identified to be associated with nicotine dependence through a genome wide 
association study (GWAS). The GWAS was performed on 1929 subjects, and a single 
nucleotide polymorphism (SNP) located within the α5 nAChR subunit gene (CHRNA5) 
was identified (Bierut et al., 2007; Bierut et al., 2008; Saccone et al., 2007). The SNP 
replaces the 398th amino acid from an aspartic amino acid (D-variant) to asparagine (N-
variant) (Bierut et al., 2008), and it is located within the second major intracellular loop 
of the nAChR subunit (Hung et al., 2008). The SNP located within CHRNA5 is noted as 
α5(D398N) (Bierut et al., 2008).  
 
Although the significance of the SNP located in the second intracellular loop of the 
human α5 nAChR subunit is unclear, animal models have elucidated some functional and 
behavioral consequences. In order to determine the functional role of the α5 N-variant 
subunit included in the heteromeric α3β4 nAChR, intracellular two-electrode voltage 
clamp was conducted on Xenopus oocytes expressing the human receptor (George et al., 
2012). The inclusion of the α5 N-variant did not change the acetylcholine dose response 
curve when compared to α3β4 nAChRs including the α5 D-variant (George et al., 2012). 
However, it reduces the maximum acetylcholine induced current response (George et al., 
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2012). The behavioral consequences of the α5 N-variant can be inferred through the 
CHRNA5 knockout mouse. The CHRNA5 knockout mouse continues to consume high 
concentrations of nicotine in comparison to the wild type (Fowler et al., 2011), this 
behavior was also reproduced by knocking down the CHRNA5 in the medial habenula 
(MHb) of rats (Fowler et al., 2011). It was concluded that the α5 nAChR subunit is 
required and necessary in the inclusion of nAChRs involved in the inhibitory pathway of 
high nicotine consumption, but not in the rewarding pathway (Fowler et al., 2011; Fowler 
et al., 2013). This data is indicative of nAChR networks that include the α5 subunit to be 
involved in smoking behavior. 
 
IV. The Ly6 Superfamily 
The superfamily Ly6 is a large family made up of proteins with specific characteristics. 
Molecules from the Ly6 superfamily have a small molecular weight ranging from 12-20 
KD and conserved 8-10 cysteine residues that form specific disulfide bonds. Commonly, 
they are phosphatidyl inositol anchored to cell surface glycoprotein’s, although they may 
also be secreted, and are encoded by murine chromosome 15 (Gumley et al., 1995). 
Initial isolation of Ly6 like proteins occurred in the immune system of the mouse 
(Gumley et al., 1995). In general, their functions were determined as T-cell activation, 
lymphocyte homing, and leukocyte migration (Gumley et al., 1995; Hanninen et al., 
1997). Since then, the superfamily of Ly6 like molecules has expanded and now includes 
proteins from invertebrates such as Drosophila and Caenorhabditis elegans to vertebrates 
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such as rat and human (urokinase plasminogen activator receptor uPAR) (Gumley et al., 
1995). 
 
Interestingly, neurotoxins such as α-bungarotoxin and cobratoxin have the Ly6 
superfamily characteristics. Neurotoxins have been isolated from the venom of multiple 
snake families (Endo and Tamiya, 1987). They were first identified as competitive 
antagonists of the nAChRs found at the motor end-plate of the neuromuscular junction 
(Endo and Tamiya, 1987). There are two groups of neurotoxins, short chain and long 
chain (Endo and Tamiya, 1987). The short chain neurotoxins are made up of 60-62 amino 
acids and have 4 conserved disulfide bonds formed between cysteine residues (Tsetlin, 
2015). The long chain neurotoxins are made up of 66-75 amino acids with 5 conserved 
disulfides bonds and a longer C-terminal tail (Tsetlin, 2015). These characteristics allow 
both the short and long chain neurotoxins to fold into a three-fingered beta structural loop 
motif (Tsetlin, 2015).This secondary protein structure is formed from their 4 conserved 
disulfide bonds (Tsetlin, 2015). The short and long chain neurotoxins are known to bind 
to the α subunit of the muscle nAChRs with high affinity (Endo and Tamiya, 1987). 
However, only the long chain neurotoxins such as alpha-bungarotoxin and cobratoxin are 
known to bind to the neuronal homomeric α7 nAChRs (Endo and Tamiya, 1987). X-ray 
and NMR structures have identified the second fingered loop of the long chain 
neurotoxins to interact with the extracellular NH2-terminal agonist binding site of the α 
nAChR subunit (Tsetlin, 2015). 
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 V. Prototoxin proteins are part of the Ly6 Superfamily  
 
Proteins identified as part of the Ly6 superfamily and expressed in the nervous system are 
termed prototoxins. Because they share protein characteristics with neurotoxins such as 
α-bungarotoxin, it is hypothesized that many prototoxins modulate nAChRs. The GPI-
linked prototoxins studied intensively are LYNX1, LYNX2, LYPD6, and prostate stem 
cell antigen (PSCA) (Darvas et al., 2009; Dessaud et al., 2006; Hruska et al., 2009; Miwa 
et al., 1999).  
 
LYNX1 was the first Ly-6-like molecule to be identified as a prototoxin. The idea that 
LYNX1 interacts with nAChRs was first supported by its localization. Through in-situ 
hybridization performed on mice brain slices, LYNX1 mRNA was identified in the 
purkinje cell body layer of the cerebellum, deep cortex layers such as layers V and VI, 
CA3 pyramidal neurons of the hippocampal formation, and mitral cells of the olfactory 
bulb (Miwa et al., 1999). The expression pattern of LYNX1 was similar to the expression 
pattern of the α4β2 and α7 nAChRs. Thus, immunofluorescently stained HEK293 cells 
transfected with the α4β2 nAChRs and LYNX1 showed co-localization (Ibanez-Tallon et 
al., 2002). Additionally, hippocampal CA3, pyramidal, and amygdala neurons stained 
positive for α7 and LYNX1 (Ibanez-Tallon et al., 2002). Following its localization, 
LYNX1 was established it as a nAChR allosteric modulator. Macroscopic currents from 
Xenopus oocytes injected with α4 nAChR subunit, β2 nAChR subunit, and LYNX1 
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cRNA exhibited a decrease in the fast time constant (tau) of desensitization (Ibanez-
Tallon et al., 2002). Also, the ACh EC50 was increased (Ibanez-Tallon et al., 2002). 
Collectively, this data was interpreted as LYNX1 increasing the desensitization rate of 
α4β2 while decreasing its sensitivity to ACh. This conclusion is further supported by 
whole cell recordings from neurons located in the medial habenula of the LYNX1 
knockout mouse. When 20µM nicotine was perfussed onto the medial habenula neurons 
of the LYNX1 knockout mouse, an increase in maximum current response was observed 
compared to wild type (Miwa et al., 2006).  
  
LYNX2 was the second Ly-6 like molecule to be identified as a prototoxin, and was also 
shown to affect behavior. An interaction between LYNX2 and nAChRs was first 
established through co-immunoprecipitation experiments performed on transfected 
HEK293 cells, which confirmed the interaction between LYNX2 with α7 and α4β2 
nAChRs (Ibanez-Tallon et al., 2002; Miwa et al., 1999; Tekinay et al., 2009). Similarly to 
LYNX1, LYNX2 also decreases the fast time constant of desensitization (tau) and 
increases the ACh EC50, as measured from Xneopus oocyte whole cell recordings 
(Tekinay et al., 2009). LYNX2, on the other hand, is linked to anxiety and fear behavior. 
The LYNX2 knockout mouse spends less time in the open arms from an elevated plus 
maze and less time in a well-lighted area (Tekinay et al., 2009). Both behavioral 
characteristics are trademarks of a more anxious and fearful mouse.  
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PSCA was the third Ly-6 like molecule to be identified as a prototoxin (Hruska et al., 
2009). Again, PSCA transcript levels correlated with CHRNA7 (α7) nAChR subunit 
transcript levels. The detection was done through qPCR on multiple chicken neural tissue 
derived from telecephalon, cerebellum, ciliary ganglia, sympathetic ganglia, and dorsal 
root ganglia (Hruska et al., 2009). PSCA was also shown to modulate the function of the 
α7 nAChR. Neurons from dissociated embryonic day 14 chicken ciliary ganglia, which 
over expressed PSCA, exhibited a decrease in intracellular Ca2+levels in response to 
10µM nicotine (Hruska et al., 2009). Also, the decreased Ca2+ influx was not further 
diminished when 50nM α-bungarotoxin was applied (Hruska et al., 2009). These results 
indicate that the expression of PSCA blocks Ca2+ influx through the α7 nAChRs (Hruska 
et al., 2009). The biological relevance of PSCA was demonstrated when it was expressed 
in the chicken ciliary ganglia at embryonic day 8 (E8) with a chicken retrovirus. Under 
these conditions PSCA rescued choroid neurons from programmed cell death (Hruska et 
al., 2009). 
  
In contrast to the other prototoxins, LYPD6 seems to behave as a positive modulator of 
nAChRs. The expression of LYPD6 was established through qPCR and in-situ 
hybridization. Both methods illustrated LYPD6 to be highly expressed in the brain, 
sympathetic ganglia, dorsal root ganglia, and the trigeminal ganglion of the mouse 
(Darvas et al., 2009). Whole cell recordings were obtained from trigeminal neurons of 
genetically enginered transgenic mice over expressing LYPD6 in order to identify 
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LYPD6 as a nAChR modulator. No change in the nicotine EC50 was observed in the 
transgeneic mice compared to wild type (Darvas et al., 2009). However, at 1 and 2mM 
nicotine an increase in inward Ca2+ currents was observed (Darvas et al., 2009).  
 
Secreted prototoxins from the Ly6 superfamily have also been identified; some examples 
of these include SLURP-1 and SLURP-2. Both of these were initially isolated from 
human blood and urine (Tsetlin 2015). Soon after, their discovery, they were shown to 
modulate nAChRs. Macroscopic ACh currents recorded from Xenopus oocytes 
expressing the α7 nAChR were increased when perfused with 20nM SLURP-1 
(Chimienti et al., 2003). In a similar fashion, SLURP-2 affected the α3 heteromeric 
nAChRs (Tsetlin 2014).  
 
In summary, the number of genes encoding Ly6 family members likely to be prototoxins 
is very large, and a number of questions on how these family members may regulate 
nicotinic signaling still remains. Although, prototoxins have a similar protein structure as 
α-bungarotoxin it is still unclear as to where these proteins are binding on nAChRs. If 
prototoxin proteins do bind to nAChRs at a competitive antagonist site, then it would be 
expected to inhibit nAChR function. However, inhibition of nAChR function has only 
been observed with LYNX1 (Miwa et al., 1999), suggesting that prototoxins bind to an 
allosteric binding site. Additionally, α-bungarotoxin is known to specifically bind and 
inhibit the function of the homomeric α7 nAChR, implying prototoxins to only inhibit 
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the function of the α7 receptor subtype. Yet, this is not the case since LYNX1 and 
LYNX2 are known to regulate the α7 as well as the α4β2 nAChRs (Miwa et al., 1999; 
Tekinay et al., 2009). All of this evidence suggests prototoxins to bind to an allosteric 
binding site on nAChRs, but it is still unclear as to how these prototoxins may be 
modulating the function of nAChRs.      
 
VI. The avian ciliary ganglion as a model for studying nAChRs 
 
The well-established characteristics of the avian ciliary ganglion make it an excellent 
model for studying nAChRs. The ganglion sits behind the eye, which makes it easy to 
access and isolate for further manipulation. It is composed of two types of neurons, 
choroid and ciliary, both having specific characteristics (Marwitt et al., 1971). The 
ganglion is innervated by neurons from the accessory ocular nucleus, which activates the 
nAChRs of the choroid and ciliary neurons in response to light. Both neuron types 
express two nAChR subtypes: the homomeric α7 and heteromeric α3* containing 
nAChRs, the latter include combinations of α3β4, α3β4α5, and sometimes α3β2 
(Corriveau and Berg, 1993; Wevers et al., 1999). Though both neurons express both 
nAChR subtypes, their localization vary according to neuron type. At avian embryonic 
day 10, the ciliary neurons form pseudospines from small somatic dendrites that over-
fold on themselves. These pseudospines are highly enriched in clustered α7 nAChRs that 
are activated by ACh spill over (Shoop et al., 2002). In contrast, the choroid neurons 
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express α7 nAChRs over the surface of the cell body. Both neuron types express the α3* 
nAChRs at postsynaptic densities, and are vital for autonomic transmission (Blumenthal 
et al., 1999; Chiappinelli and Giacobini, 1978; Corriveau and Berg, 1993; Kirchgessner 
and Liu, 1998; Mandelzys et al., 1994; Obaid et al., 1999) . There are other differences 
between the neurons, besides their nAChR expression patterns. The ciliary neurons are 
larger in size, regulate pupil diameter in response to light by innervating the ciliary 
muscle and iris, and synapses onto ciliary neurons are specialized calyx structures (Shoop 
et al., 2002). The choroid neurons are smaller in size, regulate nutrient delivery to the 
retina in response to light by innervating the choroid smooth muscle, and stain positive 
for somatostatin (Epstein et al., 1988; Meriney and Pilar, 1987). 
 
The developmental stages of the ganglion are well known, documented, and 
characterized, which has facilitated investigation on the functions of nAChRs during 
neurodevelopment. Between embryonic days 8-14 (E8-14), major steps in 
neurodevelopment are occurring. During this critical period there is a distinct nAChR 
expression pattern. A ten-fold increase in protein expression of the α3* heteromeric 
containing, as well as a six-fold increase in the α7 homomeric containing nAChRs, have 
been observed by using radiolabeled antibodies (Chiappinelli and Giacobini, 1978; 
Corriveau and Berg, 1994; Smith et al., 1985). Additionally, whole cell patch clamp 
recordings on dissociated ciliary ganglion neurons demonstrate an increase in the amount 
of inward current, capacitance, and current density for both the homomeric α7 and 
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heteromeric α3* containing nAChRs (Blumenthal et al., 1999). Thus, these observations 
implicate the α7 and α3* nAChRs in regulation of developmental processes. One major 
step in this critical developmental period is neural programmed cell death, were 50% of 
newly born neurons die (Landmesser and Pilar, 1974b). When the homomeric α7 nAChR 
selective drugs MLA and α-bungarotoxin are applied to dissociated avian ciliary ganglia 
about 90% of the neurons are rescued from the programmed cell death (Bunker and 
Nishi, 2002; Hruska and Nishi, 2007). However, when a non-selective nAChR drug is 
applied, cell death is exacerbated (Maderdrut et al., 1988; Meriney et al., 1987). These 
data suggest programmed neuron death is dependent only on current going through the 
homomeric α7 nAChR. Another critical event that occurs is neuron maturation. A 
phenotype of an immature neuron is the expression of the choloride transporter NKCC1. 
This transporter pumps Na+, K+, and larger amounts of Cl- ions into the cell; thus channel 
opening will cause an outward flow of Cl- ions and depolarize the cell membrane. 
Blocking α7 homomeric and α3* heteromeric nAChRs in the avian ciliary ganglia and 
mouse hippocampus with methyllycaconitine (MLA) and dihydro-β-erythroidine 
(DHβE), respectively, inhibited the transition of GABA from an excitatory to inhibitory 
transmission. This was attributed to an increase in NKCC1 expression and an increase in 
GABA response (Liu et al., 2006). Thus α3* and α7 nAChRs are implicated in the 
maturation of neurons within the dentate gyrus of the hippocampus as well as the avian 
ciliary ganglion (Campbell et al., 2010; Liu et al., 2006).
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VII. Purpose of this research: 
The main focus of my dissertation was to determine if the prototoxin protein, LYPD6B, 
interacted with a specific type of nAChR. This question was addressed by two different 
approaches. The first approach determined whether heteromeric α3β4* (any combination 
of α3, β4, and α5 subunits) nAChRs were affected by the presence of LYPD6B. As part 
of this project, I injected cRNA into four different Xenopus oocyte groups: 1) oocytes 
expressing a variety of human α3β4* pentamers 2) oocytes co-expressing a variety of 
human α3β4* pentamers plus LYPD6B 3) oocytes expressing a variety of human 
α3β4(α5) pentamers  and 4) oocytes co-expressing a variety of human 
α3β4(α5) pentamers plus LYPD6B. A concatemer approach was taken to restrict the 
α3β4* and α3β4(α5) stoichiometries. nAChR concatemers are designed so that every 
nAChR subunit is linked to each other; thus, the cRNA is translated as a single 
polypeptide as opposed to individual subunits. The ACh potency, desensitization rate, 
and maximum current were established using two electrode voltage clamp recordings. 
The second approach was to determine the expression pattern of LYPD6B in the avian 
ciliary ganglion and its ability to co-localize with α3β4* or α7 nAChRs. For this project, 
I genetically engineered LYPD6B to express the human influenza hemagglutinin (HA) 
epitope tag, since there are no commercial antibodies against avian proteins. The 
modified LYPD6B/HA was cloned into a chicken retrovirus in order to express 
LYPD6B/HA in the avian ganglion and perform immunocytochemistry against HA, 
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 The prototoxin LYPD6B modulates heteromeric alpha3 beta4 containing nicotinic 
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Prototoxins are a diverse family of membrane-tethered molecules expressed in the 
nervous system that modulate nicotinic cholinergic signaling, but their functions and 
specificity have yet to be completely explored. We tested the selectivity and efficacy of 
LYPD6B on α3β4, α3α5β4, and α7-containing nicotinic acetylcholine receptors 
(nAChRs). To constrain stoichiometry, fusion proteins encoding concatemers of human 
α3, β4, and α5 (D and N variants) subunits were expressed in Xenopus oocytes and tested 
with or without LYPD6B. We used two-electrode voltage-clamp to quantify responses to 
acetylcholine (ACh): agonist sensitivity (EC50), maximum agonist induced current 
(Imax), and time constant of desensitization (τ). For β4−α3−α3−β4−α3 and 
β4−α3−β4−α3−α3, LYPD6B  decreases EC50 from >631 µM to approximately 100 µM, 
reduces Imax by at least 59%, and decreases τ. For β4−α3−α5D-β4−α3 and 
β4−α3−β4−α3−α5D, LYPD6B decreases Imax by 63% and 32% respectively. Thus, 
LYPD6B acts only on (α3)3(β4)2 and (α3)2(α5D)(β4)2 and does not affect the properties 
of (α3)2(β4)3, α7, and (α3)2(α5N)(β4)2 nAChRs. Therefore, LYPD6B acts as a mixed 
modulator that enhances the sensitivity of (α3)3(β4)2 nAChRs to ACh while also 
reducing ACh induced whole cell currents. LYPD6B also negatively modulates α3β4 
nAChRs that include the α5 D common human variant, but not the N variant associated 
with nicotine dependence.  




Because nicotinic cholinergic signaling is known to be involved in an array of human 
behaviors such as learning, memory, addiction, and attention (Picciotto et al., 2000; 
Rezvani and Levin, 2001), the discovery of endogenous modulators of nicotinic 
acetylcholine receptors (nAChRs) is significant.  These modulators are proteins known as 
prototoxins, so named because they share structural characteristics with 3-fingered snake 
venom proteins such as α-bungarotoxin and cobratoxin (Miwa et al., 2011; Miwa et al., 
2012).   Prototoxins belong to a larger family known as Ly-6/ urokinase plasminogen 
activator receptor (Ly6/uPAR). At the primary structural level, prototoxin proteins have 
8-10 conserved cysteine residues that allow for the formation of disulfide bonds, 
constraining the protein to the three-fingered motif secondary structure (Holford et al., 
2009).  A number of prototoxins that are expressed in the nervous system and act as 
allosteric modulators of nAChRs have been identified. These include LY-6/neurotoxin 1 
(LYNX1), LYNX2 (also known as LYPD1), LY6H, LYPD6, and PSCA (Dessaud et al., 
2006; Horie et al., 1998; Hruska et al., 2009; Miwa et al., 1999; Zhang et al., 2010).  
 
When considering the interactions of prototoxins with nAChRs, the complexity of 
nAChR structure must be taken into consideration.  Functional nAChRs are either 
homomeric or heteromeric pentamers. Functional homomeric nAChRs can be assembled 
exclusively from α7, α8, or α9 subunits (Albuquerque et al., 2009; Elgoyhen et al., 1994) 
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while the heteromeric nAChRs are composed of combinations of α2 - α6 and β2- β4 
subunits (Albuquerque et al., 2009; Lindstrom et al., 1996). Additionally, the α7 nAChR 
subunit has the ability to form heteromeric nAChRs with α8, α5, or β2 subunits, and the 
α9 has the ability to form a heteromeric nAChR with the α10 subunit (Elgoyhen et al., 
2001; Girod et al., 1999; Keyser et al., 1993; Moretti et al., 2014; Morley et al., 1998; 
Murray et al., 2012; Rothlin et al., 2003; Thomsen et al., 2015). The varying subtypes, 
and even alternate stoichiometries within a given subtype contribute to different receptor 
properties, including channel kinetics and conductance, ligand potency, and 
desensitization rate (Albuquerque et al., 2009; Moroni and Bermudez, 2006; Moroni et 
al., 2006; Murray et al., 2012; Nelson et al., 2003; Tapia et al., 2007). The availability of 
varying combinations of α and β subunits can lead to the expression of multiple nAChR 
subtypes within the same cell (Conroy and Berg, 1995; Halvorsen and Berg, 1986; 
Vernallis et al., 1993). 
 
The modulatory effects of prototoxins on nAChR signaling have been studied in a limited 
number of nAChR subtypes.  The first prototoxin to be identified was LYNX1. An 
increase in induced acetylcholine macroscopic currents is observed when soluble LYNX1 
is perfused onto Xenopus oocytes expressing α4β2 or α7 (Miwa et al., 1999); however, 
when co-expressed with α4β2, LYNX1 increases the rate of desensitization by 
acetylcholine (Ibanez-Tallon et al., 2002; Ibanez-Tallon et al., 2004). LYNX1 knockout 
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mice also have greatly enhanced responses to ACh in the habenula (Miwa et al.), and 
similar effects were observed for LYNX2 (Tekinay et al., 2009).  
 
Because autonomic neurons express a limited number of nAChR subtypes (homomeric 
α7 and heteromeric α3β4*-nAChRs: any combination of α3 with β4 as well as α3, β4 
with α5 (Conroy and Berg, 1995; Halvorsen and Berg, 1990)), they are a useful system 
for studying the subtype selectivity of prototoxins. We previously discovered three 
prototoxins that are expressed in parasympathetic neurons of the Gallus ciliary ganglion. 
One of the prototoxins, prostate stem cell antigen (PSCA), blocks calcium influx through 
the α7 nAChRs but not α3-containing nAChR heteromers in ciliary ganglion neurons 
(Hruska et al., 2009). In addition, expressing PSCA prior to the period of developmental 
cell loss, rescues neurons from dying (Hruska et al., 2009).  
 
Here, we report that the other two prototoxins in the Gallus ciliary ganglion are LY6E 
and LYPD6B.  Of these two, LYPD6B is expressed in the nervous system 
(http://mouse.brain-map.org) (Miwa et al., 2012). We therefore hypothesized that, in 
contrast to PSCA, LYPD6B selectively modulates the function of heteromeric α3β4* 
nAChRs. Since heteromeric receptors can be composed of pentamers containing two or 
three alpha subunits, we restricted the stoichiometry by expressing pentameric 
concatemers in Xenopus oocytes (George et al., 2012).  These concatemers are composed 
of all five nAChR subunits expressed as a single fusion protein with linkers between each 
subunit that allow the polypeptide to fold into a functional pentamer (Carbone et al., 
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2009; George et al., 2012; Kuryatov and Lindstrom, 2011). The linker allows complete 
control of the subunit stoichiometry and associations to be exercised. Expression studies 
of nAChR concatemers have faithfully mimicked pharmacological properties of multiple 
natively expressed nAChR subtypes, including α3β4* nAChRs (Carbone et al., 2009; 
George et al., 2012; Kuryatov and Lindstrom, 2011). Our results show that LYPD6B 
reduces the EC50 value for ACh while also reducing the net whole cell current induced 
by ACh on α3β4 nAChRs containing three α3 subunits as opposed to those containing 
only two. In addition, LYPD6B reduces the whole cell current induced by ACh through 
α3β4* nAChRs containing the α5(D) subtype, while having no effect on the α5(N) 
subtype associated with nicotine dependence.  
 
Material and Methods 
Chemicals- All buffer components and pharmacological reagents (acetylcholine and 
atropine) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fresh stock drug 
solutions were made daily and diluted as required. 
  
nAChR concatemers and monomeric α7 plasmids- Pentameric nAChR concatemers were 
designed and constructed from human nAChR subunits with subunit sequences  
β4−α3−β4−α3-X (George et al., 2012) or β4−α3− X−β4−α3 where X is β4, α3, α5(D-
variant), or α5(N-variant).  These series generated pairs of identical pentamers that varied 
in the location of the inserted subunit X within the length of the fusion protein.  Thus, 
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these served as controls for whether isoform selective effects of LYPD6B were 
consistently observed between the two series (eg, between (α3)3(β4)2 generated by 
β4−α3−β4−α3-α3   or  β4−α3− α3−β4−α3). In order to express the concatemer as a 
single polypeptide the Kozac and signal peptide sequences were removed from all 
subunits with the exception of the first subunit. Additionally, a 40-amino acid sequence 
that includes the C-terminal tail of the preceding subunit and alanine-glycine-serine 
repeats arranged in order to encode enzyme restriction sites are inserted in the linker 
region between each subunit. In either series, the first agonist-binding site occurs between 
the negative face of the first β4 subunit and the positive face of the 
neighboring α3 subunit (George et al., 2012). Concatemeric receptors and the monomeric 
α7 subunit were expressed from the pSGEM oocyte high expression vector (George et 
al., 2012).  
 
RNA synthesis- Concatemeric plasmids were linearized with NheI for two hours at 37°C 
and treated with proteinase K for 30 min at 50°C. The DNA was purified with the Qiagen 
Qiaquick PCR purification kit protocol (Qiagen, Venlo, Limburg, Netherlands). The 
synthesis and clean up of cRNA was done by following the protocol from the mMessage 
mMachine T7 kit (Applied Biosystems/Ambion, Waltham, MA, USA). Reactions were 
treated with TURBO DNase (1 unit for 15 min at 37°C), and cRNAs were purified by 
lithium chloride precipitation. 
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Oocyte preparation and RNA injection- Ready to inject Xenopus oocytes were purchased 
from Ecocyte Bioscience (Austin, TX, USA). Oocytes were stored at 13°C in incubation 
buffer (82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl2.6H2O, 1 mM CaCl2.2H2O, 1 mM 
Na2HPO4, 5 mM HEPES, 600 µM theophylline, 2.5 mM Na pyruvate, 50 U/ml penicillin, 
50 µg/ml streptomycin, 50 µg/ml gentamycin sulfate; pH to 7.5). Injection electrodes 
were pulled glass micropipettes that were broken to achieve an outer diameter of 40 µm 
(resistance of 2-6 mΩ), and pipettes were used to inject 60 nl containing 20 ng of α3β4 or 
α3β4α5 heteromeric nAChRs cRNA/oocyte, or 10 ng of the monomeric α7 subunit 
cRNA/oocyte. The monomeric α7 subunit was co-injected with the chaperone protein 
RIC3 at a 1:50 mass ratio to enhance functional expression (Halevi et al., 2002). Oocyte 
coinjections with the receptor as well as the prototoxin LYPD6B were performed at a 1:1 
cRNA concentration by weight per oocyte.  
 
Dose and maximum current response recordings of Xenopus oocytes expressing α3β4*-
nAChR concatemers and monomeric α7-nAChRs- Recordings were performed five days 
post injection. Xenopus oocytes were voltage-clamped at -70 mV with an Axoclamp 
900A amplifier (Molecular Devices, Sunnyvale, CA, USA). Recordings were sampled at 
10kHz (low-pass Bessel filter, 40 Hz; high pass filter, DC), and the resulting traces were 
saved to disk (Molecular Devices Clampex v10.2). Data from oocytes with leak currents 
(Ileak)> 50 nA were excluded from recordings. Agonist (ACh) was applied using a 16 
channel, gravity-fed, perfusion system with automated valve control (AutoMate 
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Scientific, Inc., Berkeley, CA). All solutions contained atropine sulfate (1.5 µM) to block 
muscarinic responses. Oocytes expressing the α7 homomeric or α3β4* -nAChR 
concatemers were perfused with receptor agonist (ACh) for 5 s with 60 s washout times 
between each subsequent application.  
 
Data Analysis for LogEC50 and maximum current response- LogEC50 and maximum 
current values (Imax) was determined from individual oocytes. For the LogEC50, 
responses were normalized to the maximum current response. Normalized current 
responses were plotted against ACh concentration and the LogEC50 was determined 
through non-linear least squares curve-fitting (GraphPad Prism 6.0, GraphPad Software, 
Inc., La Jolla CA, USA) using unconstrained, monophasic logistic equations to fit all 
parameters. LogEC50 values are presented as the mean + 95% confidence interval (CI). 
For determination of LYPD6B effects on Imax, responses from oocytes coexpressing the 
nAChRs and LYPD6B were normalized to control oocytes (oocytes only expressing the 
nAChRs under question). Normalized LogEC50 and Imax responses for oocytes 
expressing a defined nAChR concatemer averaged with or without co-expression of 
LYPD6B were averaged, and then tested for significant differences between groups using 
Student’s t test (GraphPad Prism 6.0, GraphPad Software, Inc., La Jolla, CA, USA).   
 
Desensitization rate of α3β4*-nAChR concatemers 
Recordings were performed seven days post injection. Xenopus oocytes were voltage-
clamped and desensitization kinetics was measured as previously described (Eaton et al., 
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2014). 1.0 mM ACh (corresponding to the EC100 value) was applied by using 1 channel 
from a 16 channel, gravity-fed, perfusion system (AutoMate Scientific, Inc.; Berkeley, 
CA, USA). Because perfusion rates can influence channel desensitization or recovery 
from activation, the flow rate of the system (6 mL/min) was continuously monitored and 
measured between groups. Oocytes expressing concatemers were perfused with receptor 
agonist ACh for 20-45 minutes; all α5 containing nAChRs were perfused for 
approximately 20 min, (α3)3(β4)2 nAChRs were perfused for approximately 25 min, and 
(α3)2(β4)3 nAChRs were perfused for approximately 45 min. Perfusion times were 
determined according to the amount of time required for the entire population of 
receptors to reach 10% of the maximum response; this allows for an accurate 
measurement of the desensitization time constant (τ).  
 
Data Analysis for current recovery at steady-state desensitization recordings  
The rate of desensitization was determined from individual oocytes. Each oocyte’s 
current responses were observed during prolonged agonist application, and normalized to 
the maximum response in each individual case. Normalized current responses were 
plotted as a function of time, and desensitization was fitted with a one phase or two phase 
exponential decay (GraphPad Prism 6.0, GraphPad Software, Inc., La Jolla, CA, USA). 
However, there was no significant increase in the quality of fit between the one phase and 
two phase model in any of the measurements taken, either from individual oocytes or for 
averaged data across multiple oocytes. Therefore, the single-site fit model was chosen to 
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determine τ. The statistical significance of any difference between τ values in the 




Following recordings, oocytes expressing the concatemer versus concatemer plus 
LYPD6B were incubated on ice for one hour with a 1:50 dilution of primary antibody 
(concentrated mAb35 rat anti AChR; (Developmental Studies Hybridoma Bank, Iowa 
City, IA, USA,) in blocking solution (incubation buffer, 10% horse serum, and 0.1% 
sodium azide). Oocytes were then washed, fixed on ice for an hour with Zamboni’s 
fixative (0.2 M Na2HPO4, 4% paraformaldehyde, 0.2 M NaH2PO4, and 10% picric acid, 
pH 7.2), blocked, and incubated for at least one hour at room temperature in a 1:250 
dilution of biotinylated anti-mAb35 rat, (Vector laboratories, Burlingame, CA, USA) in 
modified blocking solution (block solution minus sodium azide), washed, then incubated 
at room temperature for an hour with 1:500 dilution beta-galactosidase avidin D (Vector 
laboratories, Burlingame, CA, USA). Control oocytes were incubated in modified block 
solution. Oocytes were then washed and incubated at room temperature for 24 hours with 
100µM 4-methylumbelliferyl β-D-galactopyranoside (Molecular Probes, Eugene, OR, 
USA). The reaction was stopped by adding 15µl of 10M NaOH. Fluorescence was 
measured at excitation and emission of 450 and 350 nm respectively with a Biotek 
synergy H4 hybrid reader (Biotek, Winooski, VT, USA).  
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Data Analysis for oocyte ELISA- The average relative fluorescence values per group were 
determined from each oocyte fluorescence value normalized to the average fluorescence 
of control oocytes (oocytes incubated without beta-galactosidase avidin D). Student’s t 
test (GraphPad Prism 6.0) was used to test for statistically significant differences between 
the average of relative fluorescence values of oocytes expressing the concatemer alone 




Identifying prototoxins in Gallus parasympathetic neurons 
In our previously reported study, six EST sequences similar to the structure of Mus lynx1 
were identified and three (Ch6ly, Ch3ly, and Ch5ly) were found to be expressed in the 
embryonic ciliary ganglion (Hruska et al., 2009). Ch6ly was identified as prostate stem 
cell antigen (PSCA) (Hruska et al., 2009). Prior to undertaking the present study, we 
determined by BLAST that Ch3ly is LY6E and Ch5ly is LYPD6B. Gallus LYPD6B and 
LY6E share a 72% and 44% amino acid identity respectively with the Homo sapiens 
LYPD6B and LY6E (Fig. 1A and 1B). When translated, both sequences have the 
canonical characteristics of a prototoxin protein: conserved 8-10 cysteine residues with 
defined disulfide bonding pattern that forms the three finger tertiary structure similar to 
the toxin alpha-bungarotoxin (Fleming et al., 1993). Since LYPD6B is expressed in the 
brain, we focused our attention on LYPD6B (Miwa et al., 2012). LYPD6B is located on 
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chromosome 2 and is also known as LYPD7 (Fig 1C). Though LYPD6B and LYPD6 are 
similar in name they are encoded by different genes and are not splice variants of each 
other (Fig.1C). 
 
Preferential modulation of ACh sensitivity by LYPD6B of specific concatemers 
We tested the effects of LYPD6B on four different α3β4 nAChR concatamers expressed 
in Xenopus oocytes using two-electrode voltage clamp to measure responses to ACh: two 
nAChRs with a composition of (α3)2(β4)3 having concatemeric sequences of 
β4−α3−β4−β4−α3 and β4−α3−β4−α3−β4 and two nAChRs with a composition of 
(α3)3(β4)2 having concatemeric sequences of β4−α3−α3−β4−α3 and β4−α3−β4−α3−α3. 
The current responses of Xenopus oocytes expressing each α3β4 nAChR concatemer 
were compared to those expressing the same concatemer in the presence of LYPD6B.  
The responses to different concentrations of ACh for the α3β4 heteromers are illustrated 
in Figure 2.  The EC50 value of ACh was not affected by LYPD6B in (α3)2(β4)3 
concatemers: β4−α3−β4−β4−α3 and β4−α3−β4−α3−β4 (Fig. 2A,B).  In contrast, 
LYPD6B decreases the EC50 value of ACh for (α3)3(β4)2 concatemers: 
β4−α3−α3−β4−α3 and β4−α3−β4−α3−α3 (Fig. 2C, D) from 104 µM (CI 90-120 µM) to 
22 µM (CI 20-23 µM) and 670µM (CI 638-703 µM) to 95µM (CI 85-105 µM) for 
β4−α3−α3−β4−α3 and β4−α3−β4−α3−α3 respectively).   
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In addition to α3β4, autonomic neurons express α3β4α5 nAChRs (Vernallis et al., 1993). 
Genome-wide association studies on humans have identified a rare allele of the gene 
encoding the α5 subunit CHRNA5 that is associated with nicotine dependence in 
cigarette smokers (Bierut et al., 2007; Bierut et al., 2008). The common allele of 
CHRNA5 encodes the α5 D-variant, and the allele associated with nicotine dependence 
encodes the α5 N-variant. Therefore, we tested the effects of LYPD6B on four different 
concatemers encoding α3β4α5 nAChRs. Two of the α3β4α5 nAChRs have a 
composition of (α3)2(β4)3(α5D) with sequences of  β4−α3−α5D-β4−α3 and 
β4−α3−β4−α3−α5D, and the other two are (α3)2(β4)3(α5 N) with sequences 
of β4−α3−α5N−β4−α3 and β4−α3−β4−α3−α5N. The responses to ACh of Xenopus 
oocytes expressing α3β4α5 nAChR concatemers were compared to those co-expressed 
with LYPD6B (Fig. 3). Regardless of the presence of the α5 D-variant or the α5 N-
variant, the co-expression of LYPD6B does not alter the EC50 value to ACh of the four 
different stoichiometeries tested (Fig. 3; Table 1). 
 
Since autonomic neurons prominently express homomeric α7 nAChRs in addition to 
heteromeric α3β4* nAChRs (Blumenthal et al., 1999; Vernallis et al., 1993), we tested 
the effects of LYPD6B on α7 nAChRs (Fig.4). The homomeric α7 nAChR requires the 
chaperone protein, RIC3, in order to traffic to the cell surface (Halevi et al., 2002; 
Williams et al., 2005); therefore, Xenopus oocytes were either co-injected with mRNAs 
encoding the chaperone protein RIC3 and the α7 nAChR subunit monomer at a 50:1 
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ratio, or with RIC3, α7, and LYPD6B at a 50:1:1 concentration ratio. The ACh EC50 
value for α7 nAChR homomers is not affected by the presence of LYPD6B (Fig 4; Table 
1).  
 
Preferential modulation by LYPD6B of maximum current induced by ACh in specific 
concatemers 
The second functional component tested was the maximum current response to ACh 
(Imax). LYPD6B significantly decreases the Imax of both (α3)3(β4)2 nAChR 
concatemers (β4−α3−α3−β4−α3 and β4−α3−β4−α3−α3) by approximately 30% and 
60% respectively (Fig. 5 and 6). LYPD6B does not alter the Imax for either of the two 
(α3)2(β4)3  nAChR concatemers or that of the homomeric α7 nAChRs. These differences 
in Imax cannot be attributed to differences between the number of pentamers expressed 
on the surface of the oocytes because we cannot detect any differences in cell surface 
mAb35 binding to oocytes expressing these constructs in the presence or absence of 
LYPD6B (Suppl. Fig. 1). 
 
LYPD6B decreased the Imax for the β4−α3−α5D-β4−α3 and β4−α3−β4−α3−α5D 
nAChRs by approximately 30% and 60% respectively (Fig. 5 and 6). There is no change 
in the Imax for either format of α3β4α5 concatemers tested (Fig. 6). Thus, LYPD6B 
selectively reduces the Imax of α5 D-variant containing α3β4 nAChRs compared to 
those containing the α5 N-variant associated with heavy smoking. 
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Preferential modulation of desensitization rate to ACh in specific concatemers by 
LYPD6B 
The third functional component tested was the desensitization rate of the nAChRs. For 
each nAChR, the desensitization time constant (τ) was measured during an acetylcholine 
perfusion time period long enough for the inward current to reach ten percent of its initial 
response. LYPD6B decreased the time constant for desensitization (τ) of only the 
(α3)3(β4)2  concatemers β4−α3−α3−β4−α3 and β4−α3−β4−α3−α3 (Fig. 7; Table 1), 
indicating an increase in the desensitization rate of the receptors. LYPD6B did not 
change the desensitization rates to ACh to (α3)2(β4)3  or any of the α5D or α5N 
containing α3β4 heteromers (Fig. 8). Note that our perfusion system is capable of 
exchanging solutions on a sub-second timescale (38), at least an order of magnitude faster 
than the measured τ values. This ensures that α3β4*-nAChR desensitization effects can 
be measured accurately since they (and not solution exchange effects) are by far the 
predominant contributor to the observed τ values. For the same reason, it was not 
possible to measure accurately the desensitization rate for the homomeric α7 nAChR in 
our system (α7-nAChR desensitization occurs much more rapidly than solution 
exchange) (Papke and Porter Papke, 2002). 
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Discussion 
This study identifies LYPD6B as a prototoxin that modulates the function of α3β4* 
heteromeric, but not α7 homomeric nAChRs. Further, the effects of LYPD6B are 
dependent on the particular subunit composition and stoichiometry of α3β4 containing 
nAChRs. For (α3)3(β4)2 nAChRs, LYPD6B enhances the sensitivity to ACh, yet 
decreases the Imax and increases the rate of desensitization to ACh, while these effects 
are not seen with (α3)2(β4)3 nAChRs.  When the α5 subunit is introduced, LYPD6B 
decreases the Imax induced by ACh only when the α5 D-variant is present, but has no 
effect when the α5 N-variant associated with heavy smoking is included. Importantly, 
LYPD6B had no apparent effect on ACh responsiveness of α7 subunit containing 
homomers. This demonstrates that the effects of LYPD6B on α3β4* nAChR function are 
highly subtype- and stoichiometry selective and illustrates a previously unappreciated 
complexity in prototoxin modulation of nAChRs. 
 
In comparison to the two best-studied prototoxins to date, LYNX1 and LYNX2 
(LYPD1), LYPD6B exhibits a much higher selectivity and complexity in modulating 
nicotinic signaling.  LYNX1 and LYNX2 decrease the sensitivity to ACh as well as 
enhance the rate of desensitization of both α7 homomeric and α4β2 heteromeric nAChRs 
in Xenopus oocytes (Miwa et al., 2006; Tekinay et al., 2009), thereby acting as a “brake” 
on nicotinic signaling. This is supported by studies of the LYNX1 knockout mouse where 
nicotinic responses are enhanced in the habenula (Miwa et al., 2006). LYNX1 also co-
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localizes and co-immunoprecipitates with homomeric α7 nAChRs in the amygdala, 
CA3/CA1 hippocampal neurons, and thalamic reticular nuclei (Ibanez-Tallon et al., 
2002). In contrast, LYPD6B enhances ACh sensitivity yet also decreases the Imax to 
ACh on only “low sensitivity” α3β4 pentamers containing three α3 subunits and has no 
detectable effect on α7 containing homomers. LYNX1 facilitates the assembly and 
trafficking of the low sensitivity (α4)3(β2)2 nAChRs (Nichols et al., 2014); such 
trafficking might explain the observed increase in ACh EC50 (ACh decreased sensitivity) 
of α4β2 nAChRs when expressed from subunit monomers and coexpressed with LYNX1 
(Ibanez-Tallon et al., 2002).  However, in our study, differences in nAChR subunit 
assembly cannot explain the enhanced ACh sensitivity of (α3)3(β4)2 because of the fixed 
stoichiometry of our concatemeric constructs. As a result, changes in EC50 values in our 
system must be due to a direct allosteric effect of LYPD6B on the function of (α3)3(β4)2 
nAChR.  
 
The differential responses of (α3)3(β4)2 and (α3)2(β4)3 nAChR concatemers to LYPD6B 
suggest that the additional α3/α3 interface provides a structural site for LYPD6B 
allosterism.  These two types of stoichiometries have been identified for both α3β4 and 
α4β2 heteromeric nAChRs (Moroni et al., 2006; Nelson et al., 2003) with distinct 
pharmacological properties including a higher sensitivity to ACh for the heteromers that 
contain 2 alpha nAChR subunits (Eaton et al., 2014; Harpsoe et al., 2011; Moroni et al., 
2008).  This concept of α/α interface sites for allosteric modulation is supported by the 
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observation of modulation by divalent cations at an α4/α4 interface (Moroni et al., 2008). 
When LYPD6B is coexpressed with the less sensitive (α3)3(β4)2, the EC50 to ACh 
becomes comparable to that of the more sensitive (α3)2(β4)3.  With α4β2 heteromeric 
nAChRs, the additional α4/α4 interface is thought to act equivalently to a co-agonist site 
by producing a second phase of low affinity function when it is engaged by high agonist 
concentration (Eaton et al., 2014; Harpsoe et al., 2011).  Thus, if the α3/α3 interface 
parallels the behavior of the α4/α4 interface, then LYPD6B may be influencing the 
interaction of agonist at the additional alpha-alpha interface.  Similar studies such as ours 
that constrain stoichiometry of α4β2 nAChRs while examining interaction with LYNX1 
and LYNX2 have yet to be performed. Prototoxin proteins have a similar protein 
structure to alpha-bungarotoxin, thus it is assumed that they interact with nAChRs near 
the agonist binding site (Fleming et al., 1993; Gumley et al., 1995); however, this may 
differ among prototoxins based upon structural characteristics such as the length of each 
of the three fingers and according to the nAChR subtypes with which they interact. It is 
also worth noting that many features of conventionally-recognized agonist binding 
interfaces are conserved at non agonist binding interfaces (Eaton et al., 2014; Harpsoe et 
al., 2011; Moroni et al., 2008), so prototoxin interaction sites on nAChRs could 
conceivably be located at any subunit pair interface. 
 
Our results showing that LYPD6B decreased the maximum induced ACh current 
response only in concatemers containing an α5 D-variant and not the α5 N-variant 
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suggests a possible importance in nicotine dependence. Of the many single nucleotide 
polymorphisms (SNPs) identified in CHRNA5 through a genome-wide association study 
of nicotine dependence, only one was a variant in the coding region (Bierut et al., 2007; 
Bierut et al., 2008; Saccone et al., 2007).  This SNP replaces the 398th amino acid, 
aspartic acid (D), with an asparagine (N) amino acid in the intracellular loop of the 
nAChR subunit (Bierut et al., 2008; Saccone et al., 2007).  The amino acid sequences 
surrounding the SNP are conserved across eight species, highlighting the importance of 
this region (Hung et al., 2008). The α5 subunit is known to modulate the properties of 
nAChRs in which it is incorporated (George et al., 2012; Kuryatov et al., 2011), and α5 
knockout mice as well as α5 knockdown rats exhibit reduced aversion to nicotine 
(Fowler et al., 2011; Fowler et al., 2013).  Our studies confirm our previous finding that 
nAChRs containing the α5 N-variant exhibit a decreased response to ACh when 
compared to those with the α5 D-variant. However, LYPD6B decreases the Imax to ACh 
only in α3β4 heteromers containing the normal α5D variant as opposed to the α5N 
variant associated with nicotine dependence. The fact that such a dramatic difference was 
seen in the effects of LYPD6B on α3β4 [α5D vs. α5N] suggests that individuals 
expressing the α5N-variant may lose an important mechanism for modulation of α3β4α5-
nAChR function. It is clear that considerably more studies of nAChRs and their 




Because nicotinic signaling has important functions in guiding behavior, nAChRs have 
adapted a variety of means to fine-tune their signaling. First, cells can regulate the 
subtypes of nAChRs that are expressed, and where they are expressed.  Second, neurons 
can express varying nAChR subunit stoichiometries within the same overall nAChR 
subtype(s), which further affect receptor properties. Third, prototoxin proteins belonging 
to the Ly6-uPAR family can modulate nAChR responsiveness. The data presented in this 
paper identifies LYPD6B as a prototoxin that modulates a specific stoichiometry of α3β4 
nAChR subtype as well as modulating the responsiveness of nAChRs only containing a 
specific variant of α5, serving as another means of fine-tuning nicotinic signaling. The 
exquisite selectivity for subtype, and even stoichiometry, of LYPD6B modulation of 
nAChR activity, together with the diversity of effects observed in this study, indicates 
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Table 1. The effects of LYPD6B on functional characteristics of nAChR 
concatemers The indicated parameters were measured in Xenopus oocytes expressing 
the indicated nAChR concatemers with and without coexpression of LYPD6B using two 
electrode voltage clamp after applying ACh by perfusion. Data are presented as the mean 
+ S.E., with numbers of individual oocytes tested (n). The α7 nAChRs were formed from 
mRNA encoding the CHRNA7 monomer rather than produced as a concatemer. Student’s 
t-test was performed to determine statistical significant differences between concatemeric 
nAChR function in the presence or absence of LYPD6B, * p-value< 0.05, ** p-value< 
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Figure 1. Alignment of amino acid sequences for LY6E and LYPD6B from Gallus 
gallus and Homo sapiens A. Mature protein alignment of the Gallus gallus LYPD6B, 
Genbank accession number XM_422156, and Homo sapien prototoxin LYPD6B, 
Genbank accession number XM_006712283. B. Mature protein alignment of the Gallus 
gallus LY6E, Genbank accession number NM_204775, and Homo sapien prototoxin 
LY6E, Genbank accession number NM_002346. For both A and B, asterisk identifies the 
consensus between amino acids and the shaded cysteine residues are required for a three-




Figure 2. LYPD6B decreases ACh Log EC50 for (α3)3(β4)2 heteromeric nAChRs.  
Oocytes injected, with a 1:1 RNA concentration ratio of a nAChR to LYPD6B, were 
perfused with different concentrations of ACh. Closed circles are recordings collected 
from oocytes co-expressing the receptor and prototoxin. Open circles are recordings 
collected from oocytes expressing the receptor alone. A. β4α3β4β4α3 compared to 
β4α3β4β4α3 with LYPD6B; n=11, 10, ACh concentration (10-6 to 10-2.5). B. 
β4α3β4α3β4 compared to β4α3β4α3β4 with LYPD6B; n=12, 13, ACh concentration 
(10-6 to 10-2.5). C. β4α3α3β4α3 compared to β4α3α3β4α3 with LYPD6B; n=5, ACh 
concentration (10-5.5 to 10-2). D. β4α3β4α3α3 compared to β4α3β4α3α3 with LYPD6B; 
n=17, 18, ACh concentration (10-5.5 to 10-2). Data points represent averages (+S.E), and 
the drug potency differences between the receptor versus the receptor and LYPD6B 
groups were analyzed using a student t-test (see “Materials and Methods”). 
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Figure 3. LYPD6B does not affect the ACh Log EC50 for α3β4α5  heteromeric 
nAChRs. Oocytes injected, with a 1:1 RNA concentration ratio of a nAChR and 
LYPD6B, were perfused with ACh. Closed circles are recordings collected from oocytes 
co-expressing the receptor and prototoxin. Open circles are recordings collected from 
oocytes expressing the receptor alone A. β4α3α5Dβ4α3 compared to β4α3α5Dβ4α3 
with LYPD6B; n=9, ACh concentration (10-5.5 to 10-2). B. β4α3α5Νβ4α3 compared to 
β4α3α5Νβ4α3 with LYPD6B; n=9, 8, ACh concentration (10-5.5 to 10-2). C. 
β4α3β4α3α5D compared to β4α3β4α3α5D with LYPD6B; n=9, 9, ACh concentration 
(10-5.5 to 10-2). D. β4α3β4α3α5Ν compared to β4α3β4α3α5Ν with LYPD6B; n=7, 9, 
ACh concentration (10-5.5 to 10-2). Data points represent averages (+S.E), and the drug 
potency differences between the receptor versus the receptor and LYPD6B groups were 
analyzed using a student t-test (see “Materials and Methods”). 
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Figure 4. LYPD6B does not affect the ACh Log EC50 for α7  homomeric nAChRs. 
Oocytes injected with the monomeric α7 nAChR subunit, chaperon protein RIC3, and 
prototoxin LYPD6B RNA at a 1:50:1 volume amounts respectively. They were perfused 
with ACh. Closed circles are recordings collected from oocytes co-expressing the 
receptor and prototoxin. Open circles are recordings collected from oocytes expressing 
the receptor alone A. homomeric α7 nAChR expressed as monomers compared to 
homomeric α7 nAChR with LYPD6B; n=6, 6, acetylcholine concentration (10-5.5 to 10-2). 
Data points represent averages (+S.E), and the drug potency differences between the 
receptor versus the receptor and LYPD6B groups were analyzed using a student t-test 
(see “Materials and Methods”). 
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Figure 5. LYPD6B decreases the ACh induced maximum current response for 
(α3)3(β4)2. 
An average of individual oocyte recorded traces of nAChR concatemers compared to 
concatemers co-expressed with LYPD6B. As well as a bar graph of normalized induced 
ACh response expressed as a percent normalized to the control for all of the α3β4* 
heteromeric concatemers with LYPD6B. A. β4α3β4β4α3 receptor at ACh doses (10-6 to 
10-2.25M), n=6. A1. β4α3β4β4α3 and plus LYPD6B, n=10. B. β4α3β4α3β4 receptor at 
ACh doses (10-6 to 10-2.25M), n=6. B1. β4α3β4α3β4 and plus LYPD6B. C. β4α3α3β4α3 
receptor at ACh doses (10-5.5 to 10-2M), n=6. C1. β4α3α3β4α3 and plus LYPD6B. The 
oocytes co-expressing the LYPD6B and β4α3α3β4α3 exhibit about a 30% decrease 
induced ACh maximum response p value 0.0001. D. β4α3β4α3α3 receptor at ACh doses 
(10-5.5 to 10-2M), n=6. D1. β4α3β4α3α3 and plus LYPD6B. The oocytes co-expressing 
the LYPD6B and β4α3β4α3α3 exhibit about a 60% decrease induced ACh maximum 
response p value 0.0001. and E. α7α7α7α7α7 receptor at ACh doses (10-5.5 to 10-2M), 





Figure 6. LYPD6B affects the ACh induced maximum current response for 
α3β4α5D-variant nAChRs. An average of individual oocyte recorded traces of nAChR 
concatemers compared to concatemers co-expressed with LYPD6B. As well as a bar 
graph of normalized induced ACh response expressed as a percent normalized to the 
control for all of the α3β4α5 heteromeric concatemers with LYPD6B. A. β4α3α5Dβ4α3 
receptor at ACh doses (10-5.5 to 10-2M), n=6. A1. β4α3α5Dβ4α3 and plus LYPD6B. The 
oocytes co-expressing the LYPD6B and β4α3α5Dβ4α3 exhibit about a 30% decrease 
induced ACh maximum response p value 0.0001 B. β4α3α5Νβ4α3 receptor at ACh 
doses (10-5.5 to 10-2M), n=6. B1. β4α3α5Νβ4α3 and plus LYPD6B. C. β4α3β4α3α5D 
receptor at ACh doses (10-5.5 to 10-2M), n=6. C1. β4α3β4α3α5D and plus LYPD6B. The 
oocytes co-expressing the LYPD6B and β4α3β4α3α5D exhibit about a 60% decrease 
induced ACh maximum response p value 0.0001. D. β4α3β4α3α5Ν receptor at ACh 
doses (10-5.5 to 10-2M), n=6. D1. β4α3β4α3α5Ν and (+) LYPD6B.  
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Figure 7. LYPD6B decreased the time constant (τ) from steady-state desensitization 
for α3β4* heteromeric nAChR concatemers. A. Graphs of the averaged normalized 
time in seconds versus the averaged normalized ACh current response per α3β4* nAChR 
subtype with and without LYPD6B. Expression of concatemer subtype alone is 
represented by the black trace and concatemer plus LYPD6B is represented by the gray 
trace. From left to right and top to bottom: β4α3α3β4α3, β4α3β4β4α3, β4α3β4α3α3, 
and β4α3β4α3β4 B. A quantitative bar graph of the time constant (τ) for each group. 
Concatemer alone is represented by the black bar and concatemer plus LYPD6B is 
represented by the gray bar. The β4α3α3β4α3 and β4α3β4α3α3 nAChR concatemers 
when expressed with LYPD6B showed a statistical significant decrease in the time 
constant.  p value 0.02 and 0.03 respectively. 
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Figure 8. LYPD6B did not affect the time constant (τ) from steady-state 
desensitization for α3β4α5  heteromeric nAChR concatemers. A. Graphs of the 
averaged normalized time in seconds versus the averaged normalized ACh current 
response per α3β4α5 nAChR subtype with and without LYPD6B. Concatemer alone is 
represented by the black trace and concatemer plus LYPD6B is represented by the gray 
trace. From left to right and top to bottom: 
β4α3α5Dβ4α3, β4α3α5Νβ4α3, β4α3β4α3α5D, and β4α3β4α3α5Ν B. A quantitative 
bar graph of the time constant for each group. The black bar represents concatemer alone 
and the gray bar represents concatemer plus LYPD6B. There was no statistically 
significant difference among the time constants.    
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Supplemental Figure 1. There is no difference in relative fluorescence values in 
oocytes expressing concatemers that exhibited a decrease in ACh maximum induced 
current response due to LYPD6B. A. A bar graph of relative fluorescence values. 
Concatemer alone is illustrated in the black bar and concatemer with LYPD6B is 
illustrated in the gray bar (n= oocyte). Relative fluorescence values were normalized to 
an average fluorescence value from oocytes incubated without the avidin-beta-
galactodiase. From left to right: 
β4α3α3β4α3 (n= 11), β4α3α3β4α3 plus LYPD6B (n= 11), β4α3β4α3α3 (n= 11),  
β4α3β4α3α3 plus LYPD6B (n= 13), and control oocytes injected with 
β4α3β4α3α3 (n= 6).   β4α3α5Dβ4α3 (n= 9), β4α3α5Dβ4α3 plus LYPD6B (n= 9), 
β4α3β4α3α5D (n= 13), β4α3β4α3α5D plus LYPD6B (n= 12), and control oocytes 
injected with β4α3α5Dβ4α3 plus LYPD6B (n= 4).     
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Prototoxins belong to the Ly6 superfamily and are known to modulate the function of 
nicotinic acetylcholine receptors (nAChRs). Yet, the regulation of mRNA expression and 
specificity for nAChR subtypes are still unclear. We have previously shown that PSCA 
reduces nicotine-induced increases in α7 nAChRs and that LYPD6B acts as a positive 
modulator of α3 containing heteromeric nAChRs.  In this study we used the avian ciliary 
ganglion as a model to determine if nAChR activity regulates mRNA expression and co-
localization of LYPD6B with α7 versus heteromeric α3* nAChRs. Because light is the 
stimulus driving nicotinic transmission in ciliary ganglia, we measured our two variables 
(mRNA expression and co-localization) from avian embryos kept in constant darkness 
versus constant light during embryonic day 7 (E7)-E14. The transcript levels of 
LYPD6B, CHRNA3, CHRNA5, CHRNB4, and CHRNA7 increased in ciliary ganglia 
from embryos kept in constant dark compared to embryos kept in constant light. Daily 
application of nAChR antagonist drugs, α-methyllycaconitine (MLA) and Dihydro-β-
erythroidine hydrobromide (DHβE) in embryos kept in constant light also caused an 
increase in CHRNA3, CHRNA5, CHRNB4, and CHRNA7. However, LYPD6B 
expression levels were not restored in the drug treated group. When embryos were reared 
in constant dark, LYPD6B co-localized with mAb35 binding, which recognizes α3, α5 
and β4 subunits. LYPD6B did not colocalize with alpha bungarotoxin binding, a marker 
for α7 containing nAChRs. These results provide further evidence that LYPD6B is a 




Signaling mediated by nicotinic acetylcholine receptors (nAChRs) is essential for 
controlling neural activity in the CNS and PNS. In the CNS, behaviors affected by 
nicotinic signaling are nicotine reinforcement, locomotion, working memory, anxiety, 
and depression (Picciotto et al., 2000). In the PNS nicotinic signaling is responsible for 
fast synaptic transmission at peripheral autonomic ganglia and at the neuromuscular 
junction (Campbell et al., 2010; Gray et al., 1996; MacDermott et al., 1999; McGehee et 
al., 1995; Wonnacott et al., 1989; Xu et al., 1999). Because of this extensive list of 
functions the cholinergic system has adapted a variety of mechanisms that modulate the 
nicotinic signaling.   
 
Recent studies have suggested that one means of modulating nicotinic signaling is 
through the expression of endogenous prototoxin proteins. Prototoxin proteins are part of 
the Ly6 urokinase plasminogen activator receptor (Ly-6/uPAR) superfamily (Gumley et 
al., 1995). The proteins are small (12-20 kDa), express a glycosylphosphatidylinositol 
anchor (GPI anchor) (Gumley et al., 1995), and possess conserved 8-10 cysteine residues 
that form specific disufide bonds, and allow for a tertiary three-finger motif, homologous 
to snake venom neurotoxins (α-bungarotoxin and α-cobratoxin) (Fleming et al., 1993; 





Because prototoxins share a similar protein structure to neurotoxin proteins (nAChR 
antagonists), it is hypothesized that prototoxins interact and modulate the response of 
nAChRs. Indeed, the prototoxin LYNX1 co-localizes with and increases the 
acetylcholine (ACh) induced macroscopic current generated by α7 and α4β2 nAChRs 
(Ibanez-Tallon et al., 2002; Miwa et al., 1999). An increase in the desensitization rate and 
ACh EC50 for both the α7 and α4β2 nAChRs was observed in Xenopus oocytes co-
expressing LYNX2 and α7 or LYNX2 and α4β2 nAChRs (Tekinay et al., 2009). Another 
example is seen in transgenic mice over expressing LYPD6. The over expressing LYPD6 
transgeneic mice exhibited an increase in Ca2+ influx specifically through the heteromeric 
α3* nAChRs of the trigeminal ganglia neurons (Darvas et al., 2009). All of these studies 
identify prototoxin proteins as modulators of nAChR signaling, however, they fail to 
demonstrate their specificity towards a specific nAChR subtype. 
 
The avian ciliary ganglion is a convenient model system to study the function, 
expression, and biological relevance of prototoxins. The development of the  ciliary 
ganglion has been well documented, and many critical events occur between embryonic 
day 8 (E8) and E14 (Landmesser and Pilar, 1974a, b), including programmed cell death, 
peripheral synaptogenesis, and morphological differentiation of two subtypes, choroid 
and ciliary neurons (Marwitt et al., 1971). Both ciliary and choroid neurons express two 
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subtypes of nAChRs: the homomeric α7 and the heteromeric α3 containing nAChRs 
(α3*) (Chiappinelli and Giacobini, 1978; Conroy and Berg, 1995; Vernallis et al., 1993). 
The latter group is made up of α3β4, α3β4α5, and sometimes α3β2 (Conroy and Berg, 
1995).  
 
We initially identified six prototoxin genes through a search of chicken EST databases.  
Of these, only three were expressed in the avian ciliary ganglion: prostate stem cell 
antigen (PSCA; (Hruska et al., 2009)), LYPD6B, and LY6E (Ochoa et al, submitted 
manuscript). PSCAwas not expressed at E8 but was present at E14, indicating a possible 
role in programmed cell death (Hruska et al., 2009). When PSCA was misexpressed at E8 
of the avian ciliary ganglion, choroid neurons were rescued from natural programmed 
cell death and a decrease in Ca2+ influx specifically through homomeric α7 nAChRs was 
observed (Hruska et al., 2009). Additionally, mRNA PSCA expression and co-
localization specifically with the homomeric α7 nAChR subtype in the avian ciliary 
ganglia are nAChR activity dependent (Otto. S. and Nishi R, unpublished data).  
 
In contrast to PSCA, LYPD6B selectively modulates the function of α3* containing 
nAChRs but not α7.  This was determined by systematically expressing concatemeric 
α3β4(α5) nAChRs in Xenopus oocytes with or without LYPD6B and using 2 electrode 
voltage clamp to measure responses to acetylcholine (ACh). LYPD6B decreased ACh 
EC50, increased the rate of desensitization to ACh, but decreased the maximum ACh 
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current response specifically for the α3* containing nAChRs  (Ochoa et al, submitted 
manuscript).  
 
In the present study we determined if the expression of LYPD6B and its co-localization 
with α3* nAChR subtypes are regulated by the activity of the avian ciliary ganglion 
nAChRs. The function of neurons in the ciliary ganglion is to cause pupillary constriction 
and enhance blood flow in response to light entering the eye.  This system is active by 
E10 and fully developed by E14 (Landmesser and Pilar, 1972). Because of this well-
established circuit, we utilized light as the stimulus in determining if nAChR activity 
regulated the expression of LYPD6B and its co-localization with α3* nAChRs. We also 
quantified the expression of CHRNA3, CHRNA5, CHRNB4, and CHRNA7 transcripts 
(α3, α5, β4, and α7 nAChR subunits) to determine if LYPD6B expression and the 
nAChR subunits coincided. 
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Material and Methods 
 
Tissue- Premium SPF fertile chicken eggs from Sunrise Farms were incubated at 100o F. 
Cilary ganglia were collected by dissecting avian embryos at embryonic day 14 (E14). 
 
RNA extraction and cDNA synthesis- Ciliary ganglia from E14 avian embryos was 
collected and immediately flash frozen with dry ice. The RNA extraction was performed 
with the TRI reagent (Molecular Research Center, Cincinnati, OH)/ chloroform method. 
The cDNA was reverse transcribed from 1µg of total RNA with the Superscript III 
enzyme, oligo-dT, and random hexamers from the Superscript III reverse transcriptase kit 
(Invitrogen, Carlsbad, CA).   
 
Real-time quantitative PCR (qPCR)- qPCR for LYPD6B was performed on the 7500 
standard Real-Time PCR system (Applied Biosystems, Waltham, MA) using TaqMan 
probe and primers. Probe was labeled with 6 FAM reporter dye at its 5’ end and black 
hole quencher (BHQ) at their 3’ end. Primer set for LYPD6B was designed against 
LYPD6B nucleic acid sequence, Genbank accession number XM_422156. LYPD6B 
forward primer 5’ GGAGAACCTCGGGTGGCAGC3’ and reverse primer 5’ 
CACACCTTCCCACTGTCCTCCACA 3’. qPCR for the CHRNA3, CHRNA5, 
CHRNB4, and CHRNA7 transcripts were performed by using TaqMan Gene expression 
assays (Applied Biosystems/Ambion, Waltham, MA). The constitutive gene control used 
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to normalize gene expression was chicken S17 ribosomal binding protein (Chrps) 
(Darland et al., 1995). The forward primer: 5’ AACGACTTCCACACCAACAA 3’ and 
the reverse primer: 5’ CTTCATCAGGTGGGTGACAT 3’. Relative transcript expression 
and number was determined using Sequence Detection Software (SDS) version 1.4.  
 
Designing and cloning LYPD6B/HA-RCASBP(A): The insertion of the human influenza 
hemagglutinin (HA), amino acid sequence YPYDVPDYA was done with site-directed 
mutagenesis through PCR using the QuikChange II site-directed mutagenesis kit (Agilent 
Technologies, Santa Clara, CA). The forward primer is as follows 5’ 
CCCCACTCCATTTCCAAACAGTTTTTATCCTTATGATGTTCCTGATTATGCTAA
GTGCTTTACCTGTG 3’. The reverse primer is as follows:  
5’CACAGGTAAAGCACTTAGCATAATCAGGAACATCATAAGGATAAAAACTG
TTTGGAAATGGAGTGGGG 3’. The HA epitope tag was inserted in frame into the full 
length of LYPD6B after the signal sequence but before the three finger-motif. The 
modified LYPD6B expressing HA was then cloned into the Slax13Nco1 plasmid. For in 
frame amino acid reading of LYPD6B/HA cloning must be done into the 5’ Nco1 and 3’ 
BamH1 restriction sites of slax13Nco1 (Morgan and Fekete, 1996). To clone into the 
restriction sites stated above an internal Nco1 enzyme restriction site was removed, 5’ 
Nco1 site was add, and a 3’ BamH1 site was added with site-directed mutagenesis as 
previously stated. The LYPD6B/HA-slax13Nco1, was cut with Cla1, and the LYPD6B-




Concentrating LYPD6B/HA-RCASBP(A) virus: Infective LYPD6B/HA-RCASBP(A) 
viral particles were generated by transfecting DF-1 chicken fibroblast cells with 1µg of 
LYPD6B/HA-RCASBP(A) plasmid DNA using Lipofectamine 3000 Transfection Kit 
(Invitrogen, Carlsbad, CA). Conditioned media containing viral stocks collected from 
DF-1 cells were concentrated ~ 20-fold by ultra-centrifugation at 90,000 x g at 4oC for 3 
hours (Morgan and Fekete, 1996). Concentrated stocks were titered by limiting dilution 
and infectivity of cells as measured by staining with Charles River rabbit antiserum 
p27gag antibody. Stocks with concentration of > 107 infectious particles/ml were used for 
in vivo infection. Viral particles (60-120 nl) were injected into the mesencephalic 
enlargement of the neural tube of Hamburger/Hamilton stage (St.) 8-9 or St. 10-13 
embryos using Drummond Nanoject microinjector. The shells were sealed with a glass 
coverslip and sterile vacuum grease and incubated at 37oC to the desired stage.   
    
Exposure of avian embryos to constant light or dark: Avian embryos were windowed at 
Hamburger/Hamilton stage 9 and incubated in Model “1502” circulated Air Incubator 
(G.Q.F Manufacturing Co, Savannah, GA) set to 100oF. Once avian embryos reached E8 
the three groups (constant dark addition of saline, constant light addition of saline, and 
constant light addition of MLA+DhβE) were incubated in two side-by-side sister clear 
plastic lidded Marsh Automatic incubators (Lyon Electronic Co, San Diego, CA). Both 
incubators were maintained at a constant temperature of 100oF and water was added as 
needed to maintain a constant humidity. The group kept in constant darkness had its 
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plastic lid entirely covered in aluminum foil. The group kept in constant light was kept in 
an incubator with a fluorescent light (Helical 20Watt CFL mercury bulb, GE, Fairfield, 
CT) suspended above it and left on 24 hours a day until embryos were harvested. The 
addition of 100 µl of saline and drugs onto the embryos was done daily. Saline (0.9% 
NaCl) or an  MLA+DhβE drug cocktail in saline was added to yield a final concentration 
of 20 nM MLA (Sigma Aldrich St. Louis, MO) and 5 µM DhβE (Sigma Aldrich St. 
Louis, MO) dripped onto the chorioallantoic membrane. Concentrations were calculated 
assuming an average 60ml volume per egg (Kaiser et al., 2002; Liu et al., 2006). 
 
Dissociating and staining E14 avian ciliary ganglia neurons- Ciliary ganglia collected 
from E14 chicken embryos were dissociated in 1mg/ml collagenase (catalog #4176; 
Worthington, Lakewood, NJ), 1mg/ml hyaluronidase (catalog # 2592; Worthington) and 
10 mg/ml bovine serum albumin (BSA; Sigma Aldrich St. Louis, MO) dissolved in 
Earle’s balanced salt solution (EBSS) at 37oC for 15 min. Reaction was terminated by 
diluting in EBSS; cells were further dissociated by incubating ganglia for 5 min in 0.3% 
trypsin (catalog # 3703; Worthington) at 37oC followed by trituration. Reaction was 
terminated with EBSS and 10% (v/v) heat inactivated horse serum, 2% (v/v) fetal bovine 
serum (Invitrogen, Carlsbad, CA), 52U/ml penicillin, 50mg/ml streptomycin and 2 mM 
glutamine, and 20 ng/ml GDNF (PeproTech, London, UK). 
 
 Cells were plated on poly-d-lysine (0.5 mg/mL of Borate Bufffer) and laminin (1 mg/mL 
of PBS) coated glass cover slips at a 1.5-2 ciliary ganglia/per coverslip concentration and 
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incubated at 37oC for 3 hours (acute culture) to allow neurons to settle before being 
labeled. After 3 hours of incubation neurons were stained and processed. Cover slips 
containing neurons were incubated at room temperature for 15 minutes in zamboni’s 
fixative (0.2 M Na2HPO4, 4% paraformaldehyde, 0.2 M NaH2PO4, and 10% picric acid 
pH to 7.2). The cells were then washed three times with EBSS and incubated on ice for 
an hour with the called for primary antibody. Primary antibodies diluted in EBSS: 
concentrated rat anti mAb35 (Developmental Studies Hybridoma Bank, Iowa City, IA, 
1:50 dilution); mouse anti HA (Covance, Princeton, NJ, 1:1000); and Alexa-488 
conjugated α-bungarotoxin (Invitrogen, Carslbad, CA, 1:500 dilution at a final 
concentration of 2nM). The cells were then rinsed three times with EBSS and placed in 
blocking solution (1X PBS and 10% horse serum) for at least an hour at room 
temperature. Followed by an hour at room temperature incubation  
with secondary antibodies diluted in EBSS: Alexa fluor 488-conjugated affinity purified 
donkey anti-rat (Jackson ImmunoResearch Laboratores, West Grove, PA, 1:800, 1.6 nM) 
and Cy3-conjugated affinity purified donkey anti-mouse (Jackson ImmunoResearch 
Laboratores, West Grove, PA, 1:800, 1.6 nM), then rinsed three times with EBSS and 
attached to a colorfrost slide (Fisher Scientific, Waltham, MA) using Mowiol 
(Calbiochem/EMD Biosciences, San Diego, CA). 
 
Imaging ciliary ganglia cells - Cells were imaged in the UVM Neuroscience COBRE 
Imaging Core Facility with a 60X/1.4 Plan Apochromatic objective using 1.512 refractive 
oil, on an inverted Olympus IX70 scope using a DeltaVision Deconvolution Restoration 
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Microscopy system (Applied Precision, Issaquah, WA) attached to a CoolSNAP HQ 
CCD camera using interline Sony ICX285 CCD (Photometrics, Tucson, AZ). Data 
acquisition was set at 0.1um/pixel. Thresholds were established using no primary 
controls. Serial optical sections were acquired in 200 nm steps inclusive of the entire 
volume of the cell. The entire coverslip was panned for cells and imaged. Images were 
deconvolved using SoftWoRx image analysis software version 3.5.1 (Applied Precision 
Inc., Issaquah, WA). Deconvolution uses iterative algorithms to de-blur the 3-D image 
stack, increase the contrast, reduce background, and capacitate resolution to exceed the 
Raleigh limit (Landmann and Marbet, 2004; McNally et al., 1999). Deconvolution used 
10 iterations per stack. Three-dimensional (3D) reconstructions were created from 
deconvolved images.  
 
Pearson Coefficient analysis- 3D images were converted into 2D projections using 
SoftWoRx Vision software. Using SoftWoRx, a Pearson’s coefficient was measured in 
order to quantify the amount of colocalization between two channels, (480-500nm FITC 
and 541-569nm Cy3). The Pearson’s coefficient provides a value describing the linear 
relationship between two channels in all the voxels of a 2D image. This can range from -
1 to 1. However, 0 and negative numbers indicate a lack of colocalization. The higher the 
number is, above 0, the greater the degree of colocalization. The Pearson’s coefficient 
obtained is for the entire cell body of the deconvolved 2D image. The mean Pearson 
coefficient + standard error (SEM) was calculated. These Pearson’s coefficients were 
analyzed for significance using Graphpad Prism software (GraphPad Prism 6.0, 
 93 
GraphPad Software, Inc., La Jolla CA). Unless otherwise noted two-tailed student t-test 






Transcript expression and immunofluorescence of LYPD6B in the presence and absence 
of nAChR activity 
In order to determine if the expression of LYPD6B is regulated through nAChR activity, 
E7 embryos were incubated for 7 days under three conditions: constant light exposure 
with a daily application of saline, constant dark exposure with a daily application of 
saline, and constant light exposure with a daily application of a final concentration of 20 
nM of MLA and 5 µM of DhβE, which completely blocks nicotinic transmission through 
the ganglion. LYPD6B mRNA levels were higher in the ciliary ganglia of avian embryos 
kept in constant darkness compared to the ciliary ganglia of avian embryos kept in 
constant light (fig. 1A). However, the LYPD6B mRNA levels were not restored in the 
third group of embryos kept in constant light with a daily application of nicotinic 
antagonists MLA and DhβE (fig. 1A). The expression of CHRNA3, CHRNA5, CHRNA7 
and CHRNB4 transcripts were also higher from ciliary ganglia of avian embryos kept in 
constant dark versus constant light (fig 1B). Furthermore, application of the nicotinic 
antagonists, MLA and DhβE, also exhibited an increase in CHRNA3, CHRNA5, 
CHRNA7 and CHRNB4 mRNA levels comparable to that of embryos kept in the dark.  
 
Because it is known that LYPD6B increases the ACh sensitivity of the α3* heteromeric 
nAChRs, we hypothesized that LYPD6B would specifically co-localize with the α3* 
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nAChRs in the avian ciliary ganglia and that this co-localization is regulated by nAChR 
activity. Co-localization between LYPD6B and α3* was determined by staining neurons 
from dissociated ciliary ganglia through immunocytochemistry. However, there are 
currently no commercial available antibodies against avian prototoxin proteins.  
Thus, we genetically engineered LYPD6B to express a human influenza hemagglutinin 
(HA) epitope tag. The HA epitope tag was inserted after the signal sequence but before 
the three finger motif (fig 2A). We then inserted LYPD6B/HA into an avian retrovirus 
plasmid. Avian df-1 fibroblasts cells were transfected with the LYPD6B/HA retrovirus 
plasmid, so that the active virus could be collected and concentrated from the cell media. 
Proper processing of LYPD6B/HA was determined with a Western blot against the HA 
epitope tag of LYPD6B from transfected versus non-transfected avian df-1 fibroblasts 
cells. The Western blot shows three bands: 14kDa, 17kDa, and 20kDa (fig 2B). The 
entire protein length, signal sequence, and GPI cleavage site for LYPD6B are identified 
and documented on ensembl (www.ensembl.org).  Thus, it was determined that each 
band represents the expected processed LYPD6B proteins. The 20kDa band represents 
the full length LYPD6B with the addition of HA, the 17kDa represents LYPD6B/HA 
minus the signal sequence, and the 14kDa represents LYPD6B/HA minus the signal 
sequence and GPI linkage (fig 2B). 
   
LYPD6B specifically co-localizes with a3* heteromeric nAChRs 
In order to characterize the co-localization of LYPD6B and nAChRs within the avian 
ciliary ganglia, we performed immunocytochemistry on neurons from dissociated ciliary 
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ganglia and calculated a Pearson’s coefficient of co-localization. The Pearson’s 
coefficient is statistically significant for the co-localization of LYPD6B and α3* nAChRs 
from the ciliary ganglion of avian embryos kept in constant darkness versus avian 
embryos kept in constant light with the addition of saline (from a Pearson’s coefficient of 
0.4530 + 0.026; n=13 to 0.3653 + 0.0308; n=13; p value < 0.05) (Table 1, fig 3A-C).  
 
Since LYPD6B is known to modify the function of α3* nAChRs and not α7, we wanted 
to determine if LYPD6B specifically co-localized with α3* and not α7 nAChRs. This 
was done by comparing the measured Pearson’s coefficient for the co-localization 
between LYPD6B and α3* versus LYPD6B and α7 nAChRs, from previously stained 
cells. The Pearson’s coefficient is significantly higher for the co-localization of LYPD6B 
and α3* nAChRs in the ciliary ganglion of avian embryos kept in constant darkness 
compared to the co-localization of LYPD6B and the homomeric α7 nAChRs  (from 
0.4530 + 0.026; n=13 to 0.139 + 0.022; n=4; p value 0.0001) (fig. 4A, B, and E). The 
Pearson’s coefficient is also significantly higher for the co-localization of LYPD6B and 
α3* nAChRs in the ciliary ganglia of avian embryos kept in constant light compared to 
the co-localization of LYPD6B and the homomeric α7 nAChRs (from 0.3653 + 0.0308; 






This study aimed to 1) determine the regulation of LYPD6B mRNA expression 2) to 
determine the condition/s necessary for specific co-localization between LYPD6B and 
α3* nAChRs and 3) to further support LYPD6B specificity towards α3* nAChRs. 
Although there is a correlation of gene expression between LYPD6B and CHRNA3, 
CHRNA5, CHRNB4 and CHRNA7 transcripts, their gene expressions seem to be 
regulated by two different mechanisms. Interestingly CHRNA3, CHRNA5, CHRNB4 
and CHRNA7 transcripts seem to be regulated by a nAChR activity mechanism, whereas 
LYPD6B seems to be regulated independent of nAChR activity. Additionally, a 
mechanism dependent on nAChR activity also seemed to drive the co-localization of 
LYPD6B and α3* nAChRs. Lastly LYPD6B failed to co-localize with the α7 nAChRs, 
which further supports the specificity LYPD6B exhibit towards the α3* nAChRs. 
 
Because LYPD6B modulates the function of α3* nAChRs, we hypothesized that nAChR 
activity would regulate the expression of LYPD6B. The LYPD6B expression levels were 
quantified through qPCR, which gives insight to transcript levels and does not necessarily 
translate to the amount of protein. However, LYPD6B is known to regulate the channel 
properties of the α3* nAChRs (Ochoa and Nishi, submitted manuscript), thus its 
biological function suggest the relevance of translating LYPD6B transcript levels. 
Therefore, we conclude that the transcript expression levels of LYPD6B are equivalent to 
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the amount of protein levels. The mRNA levels of LYPD6B increased from E14 embryos 
lacking an active nAChR activity (embryos kept in the dark), implying LYPD6B 
expression to be regulated by nAChR activity. Yet, blocking nAChR activity with 
nAChR antagonist drugs failed to restore LYPD6B expression levels, comparable to the 
levels found from embryos kept in the dark. Thus, a mechanism independent of nAChR 
activity must be involved in the regulation of LYPD6B gene expression. We then went 
on to investigate the expression of CHRNA3, CHRNA5, CHRNB4, and CHRNA7 
transcripts. CHRNA3, CHRNA5, CHRNB4, and CHRNA7 transcripts increased from 
avian embryos lacking nAChR activity (embryos kept in the dark), but in contrast to 
LYPD6B, embryos having nAChR activity blocked exhibited an increase in CHRNA3, 
CHRNA5, CHRNB4, and CHRNA7 transcripts comparable to the levels observed in 
embryos lacking nAChR activity. In this case CHRNA3, CHRNA5, CHRNB4, and 
CHRNA7 transcripts seem to be regulated by nAChR activity, at least in the developing 
ciliary ganlion. Such observation is similar to what is observed in the extensor digitorum 
longus muscle of adult rats, in which stimulation of the muscle decreased the amount of 
acetylcholine receptors expressed on the surface of the muscle (Fambrough, 1979). In 
conclusion, the expression of LYPD6B and CHRNA3, CHRNA5, CHRNB4, and 
CHRNA7 transcripts coincide with each other but seem to be regulated by two different 
mechanisms: one independent of nAChR activity and the other dependent on nAChR 
activity.   
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Though there is an extensive amount of research identifying neural innervation as a 
regulator of nAChR gene expression, it is controversial as to whether this is due to nerve 
activity or a released growth factor. All of the experiments severed the pre- and 
postganglionic inputs, nerves coming from the accessory oculomotor nucleus and exiting 
the ciliary ganglion respectively from post-hatched chickens (Boyd et al., 1988; Jacob 
and Berg, 1987, 1988; McEachern et al., 1989). Using quantitative PCR, microscopic 
images, radioiodinated antibodies, and Northern blot, researchers determined that the 
mRNA expression of nAChR subunits of the ciliary ganglion of newly hatched chickens 
are regulated through innervation and target tissues (Brumwell et al., 2002; Jacob and 
Berg, 1987; Levey et al., 1995; McEachern et al., 1989). It is clear that the innervating 
nerve is regulating nAChR expression, however, none of these studies aimed to identify 
the factor/s released from the innervating nerve. Furthermore, innervation to the avian 
ciliary ganglion and synaptogenesis of the ganglion to its targets occurs between E4-E14 
(Landmesser and Pilar, 1974), thus, these studies identify neural innervation as a 
component of nAChR gene expression after these events have occurred. In contrast, this 
study identifies a mechanism of nAChR subunit mRNA expression during the 
development of innervation, synpatogenesis, and programmed cell death.  
 
The idea of a prototoxin protein interacting with all nAChRs subtypes is supported by the 
LYNX1 studies. Through in-situ hybridization and immunocytochemistry, LYNX1 
mRNA and protein was demonstrated to be present in the deep layers of the cortex, 
hippocampus, and cerebellum a pattern similar to the α4β2 and α7 nAChRs in the Mus 
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musculus brain (Albuquerque et al., 2009; Albuquerque et al., 1995; Alkondon and 
Albuquerque, 2004; Miwa et al., 1999; Role and Berg, 1996). Additionally, the use of a 
monoclonal antibody against purified LYNX1 protein demonstrated co-localization of 
LYNX1 and α4 as well as α7 nAChRs within the neurons of the cortex, amygdala, 
habenular complex, and substantia nigra (Ibanez-Tallon et al., 2002). In that same study 
LYNX1 was shown to increase the ACh induced macroscopic current in both α4 and α7 
nAChRs (Ibanez-Tallon et al., 2002). These data identify LYNX1 as a promiscuous 
prototoxin, modulating different nAChR subtypes. In contrast, this study determines 
LYPD6B to co-localize exclusively with the α3* nAChR subtypes. Such observation is 
further supported by the macroscopic current recordings collected on Xenopus oocytes 
co-expressing LYPD6B and α3* nAChRs (Ochoa. V. and Nishi R, manuscript in 
preparation). LYPD6B decreased the ACh EC50, time constant desensitization rate (tau), 
and maximum induced current response for the low sensitivity (α3)3(β4)2 nAChRs but did 
not affect the α7 homomeric nAChRs (Ochoa and Nishi, submitted manuscript).  
 
Lastly, the most interesting data collected in this study was the observed co-localization 
between LYPD6B and α3* nAChRs to occur in the absence of nAChR activity (embryos 
kept in constant darkness). The co-localization of LYPD6B and α3* nAChRs implies an 
important function in increasing ACh potency for the α3* in the absence of nAChR 
activity. The biological importance of such co-localization, in the avian ciliary ganglion, 
was not investigated in this study. However, an intriguing idea is maintaining 
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homeostatic activity within a circuit. Two concepts identified as regulators of 
homeostatic activity are: 1. Balance between excitatory and inhibitory inputs and 2. An 
excitatory threshold set point within each neuron (John and Berg, 2015). Modifying these 
two processes can affect the homeostatic activity of an intact neural circuit, and have 
aberrant effects. Thus, neurons must express mechanisms that allow the restoration of 
their homeostatic activity. 
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Table 1.  α3* nAChRs but not α7  colocalize with LYPD6B. A table summarizing the 
Pearson’s coefficient for the co-localization of nAChRs and HA (the presence of α3* 
nAChRs and LYPD6B). As well as the Pearson’s coefficient for the co-localization of α-








HA/ mAb35 0.4530 + 0.026; n=13 0.3653 + 0.0308; 
n=13 




Figure 1. Lack of nAChR activity increases nAChR subunit mRNA levels, but does 
not increase LYPD6B. A. Quantitative PCR on LYPD6B from avian ciliary ganglia kept 
in constant light, dark, and light plus an addition of MLA/DhβE. mRNA levels for 
LYPD6B increased in the group kept in constant darkness compared to the group kept in 
constant light and constant light with the addition of MLA/DhβE; n=4; p value ~0.01. B. 
Quantitative PCR on α3, β4, α5, and α7 nAChR subunits from avian ciliary ganglia kept 
in constant light, dark, and light plus an addition of MLA/DhβE. mRNA levels for all 
nAChR subnits increased in the group kept in constant darkness as well as the group kept 
in constant light with the additon of MLA/DhβE compared to the group kept in constant 




Figure 2. Genetically engineered LYPD6B expresses HA epitope tag. A. Western blot 
identifies LYPD6B to be a glycosylphosphatidylinositol anchored protein. A. A cartoon 
image of LYPD6B protein with the insertion of the HA epitope tag. B. A Western blot of 
avian df-1 fibroblast cells not infected versus infected with the avian retrovirus 




Figure 3. LYPD6B colocalizes with α3* nAChRs in the ciliary ganglia of avian 
embryos kept in constant darkness. A. An image of a neuron stained for HA in red and 
α3* nAChRs in green from dissociated ciliary ganglia of avian embryos kept in constant 
darkness. The arrows indicate colocalization. B. An image of a neuron stained for HA in 
red and α3* nAChRs in green from dissociated ciliary ganglia of avian embryos kept in 
constant light. C. A graph of each neuron’s Pearson’s coefficient from the two groups: 
avian embryos kept in constant darkness versus constant light. There is a higher 
Pearson’s coefficient for LYPD6B and α3* nAChRs from avian embryos kept in 
constant darkness (n = 13) versus constant light (n = 13); p value < 0.05.    
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Figure 4. LYPD6B colocalizes with α3* nAChRs but not α7  in the ciliary ganglia of 
avian embryos kept in constant darkness and light. A. An image of a neuron stained 
for HA in red and α3∗ nAChRs in green from dissociated ciliary ganglia of avian 
embryos kept in constant darkness. B. An image of a neuron stained for HA in red and α7 
nAChRs in green from dissociated ciliary ganglia of avian embryos kept in constant 
darkness. C. An image of a neuron stained for HA in red and α3∗ nAChRs in green from 
dissociated ciliary ganglia of avian embryos kept in constant light. D. An image of a 
neuron stained for HA in red and α7 nAChRs in green from dissociated ciliary ganglia of 
avian embryos kept in constant light. E. A graph of each neuron’s Pearson’s coefficient 
from the four groups: avian embryos kept in constant darkness stained for LYPD6B and 
α3* versus neurons stained for LYPD6B and α7 nAChRs. Avian embryos kept in 
constant light stained for LYPD6B and α3* versus neurons stained for LYPD6B and α7 
nAChRs. There is a higher Pearson’s coefficient for LYPD6B and α3* nAChRs (n = 13) 
versus LYPD6B and α7 (n = 4) from the avian embryos kept in constant darkness as well 
as embryos kept in constant light (n = 13, 6, respectively), p value 0.0001 and 0.01 





SUMMARY AND CONCLUSIONS 
 
 
The principal finding in this dissertation is the identification of another prototoxin 
member of the Ly6 superfamily, LYPD6B, which specifically modifies function and co-
localizes with α3* containing heteromeric nAChRs. Xenopus oocytes co-expressing 
human LYPD6B and α3* nAChRs exhibited an increase in ACh sensitivity, 
desensitization rate, and a decrease in the ACh induced maximum current response for 
the low sensitivity (α3)3(β4)2 nAChR subtype, but no functional effects were observed 
for the homomeric α7 nAChR. Additionally, LYPD6B only decreased the maximum 
ACh-induced maximum current for the α3* heteromeric nAChRs containing an α5 D-
variant and not the α5 N-variant associated with nicotine dependence. Furthermore, in 
the avian ciliary ganglion of embryos kept in constant darkness (reduced nAChR 
activity), LYPD6B co-localizes with α3* heteromeric, but not with α7 homomeric 
nAChRs. These results identify a mechanism in modifying the amount of nicotinic 
signaling a cholinergic neuron receives. The biological relevance of such modulation, 
within the context of the avian ciliary ganglia, will be explored in this discussion.   
 
Programmed cell death during neurodevelopment is well studied in the avian ciliary 
ganglion. Programmed cell death is known to occur between stage 34 and 40, which is 
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equivalent to embryonic day 8-14 (E8-E14) (Landmesser and Pilar, 1974b). During this 
period about 50% of the ciliary ganglion neurons are eliminated, and because peripheral 
synaptogenesis is also occurring, neuron survival seems to be supported by target 
released neurotrophic factors. Indeed, such conclusion is supported by the rescuing of 
ciliary ganglion neurons due to the over-expression of chCNTF in vivo (Finn et al., 1998; 
Finn and Nishi, 1996). However, a significant number of neurons die at E6 well before 
synaptogenesis has occurred, implying that there is another mechanism involved in 
supporting neuron survival.  
 
The activity of nAChRs is involved in programmed cell death during neurodevelopment 
of the avian ciliary ganglion. Blocking activity through the nAChRs exacerbated cell 
death during this programmed cell death period. More specifically avian embryos treated 
with chlorisondamine, pempidine, or d-tubocurare reduced the survival of the neurons 
(Maderdrut et al., 1988; Meriney et al., 1987). Yet, application of specific α7 nAChR 
antagonist, such as α-bungarotoxin (αbtx) and methyllycaconitine (MLA), rescued 
ciliary ganglion neurons (Bunker and Nishi, 2002; Hruska and Nishi, 2007), an indication 
that a signal specifically through the α7 nAChRs induces cell death during the 
programmed cell death period. Thus, neurons must express a mechanism that regulates 
α7 signaling.  
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Because the current identified prototoxins reduce the amount of inward current going 
through the nAChRs, we hypothesized PSCA to interact with α7 nAChRs and reduce the 
amount of inward current, and this reduction in inward current is a mechanism in 
supporting neuron survival during programmed cell death. This hypothesis was further 
supported by two sets of evidence 1. in-situ hybridization and qPCR methods both 
illustrate a correlation in expression between PSCA and α7, suggestive of an interaction 
between the two proteins and 2. PSCA expression pattern, absent at E8 present at E14, 
suggest PSCA to have a function in programmed cell death.  The hypothesis was then 
tested by misexpressing PSCA in the avian ciliary ganglion at E8 and determining if 
ciliary ganglion neurons were rescued from their programmed cell death phenomena 
(Hruska et al., 2009). It was concluded that PSCA misexpression rescued only the 
choroid neurons (Hruska et al., 2009). In order to demonstrate that the choroid neuron 
survival was due to a decrease in α7 activity calcium imaging was performed on 
dissociated E8 ciliary ganglia, that over expressed PSCA, in the presence of TTX and 
cobalt (Hruska et al., 2009). The ciliary ganglia neurons exhibited a [Ca2+]i decrease in 
response to 10µM nicotine, and the current response could not be further reduced with 
the application of αbtx, suggestive that the residual Ca2+ response is due to the α3* 
nAChRs (Hruska et al., 2009). In conclusion PSCA is acting as a negative modulator 
(brake) and reducing the function specifically for the α7 nAChR and the interaction of 
PSCA and α7 rescues choroid neurons from their programmed cell death process.  
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Since, PSCA regulates the activity of α7 nAChRs we hypothesized that its mRNA 
expression and co-localization to be nAChR activity dependent. When avian embryos 
were kept in constant light exposure PSCA expression levels increased (Otto and Nishi, 
unpublished), presumably because of an increase in nAChR activity. Furthermore, the 
constant light exposure drove a higher Pearson’s coefficient for the co-localization 
between PSCA and α7 in ciliary and choroid neurons, whereas a smaller Pearson’s 
coefficient was observed for the co-localization of PSCA and α3* nAChRs (Otto and 
Nishi, unpublished data). The major conclusion drawn from these experiments is the 
specificity of PSCA towards the α7 nAChRs seems to be driven by nAChR activity. 
 
In contrast to PSCA, LYPD6B is a complex allosteric modulator specifically for the α3* 
heteromeric nAChRs. In the presence of LYPD6B low ACh concentrations are able to 
activate the (α3)3(β4)2 nAChRs and allow current to flow through (reference to Chapter 
2). However, as ACh concentrations increase LYPD6B decreases the amount of current 
that may flow through the (α3)3(β4)2 receptors as seen in the reduced Imax (reference to 
Chapter 2). Additionally, LYPD6B does not affect ACh potency for (α3β4)2(α5D-
variant) nAChRs, but does decrease the amount of current flowing through the receptor 
(reference to Chapter 2). In this aspect LYPD6B behaves similarly to PSCA, where a 
decrease in nAChR function is observed due to a prototoxin.  
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Because the expression of PSCA was increased by nAChR activity, we questioned if 
LYPD6B was also regulated by the same mechanism. Again avian embryos were kept in 
constant light, but this time LYPD6B mRNA levels failed to increase (reference to 
Chapter 3). They did however increase from embryos kept in constant darkness. These 
data show LYPD6B does not increase with nAChR activity. Furthermore, the constant 
darkness drove a higher Pearson’s coefficient for the co-localization between LYPD6B 
and α3* in ciliary ganglia neurons, whereas the opposite was observed for the co-
localization of LYPD6B and α7 nAChRs (reference to Chapter 3). In conclusion PSCA 
and LYPD6B act through opposing mechanisms, possibly to promote cell survival. PSCA 
protects neurons from programmed cell death by reducing excessive influx through α7 
nAChRs. In contrast, LYPD6B enhances ACh sensitivity of the α3* nAChRs, which may 
promote trophic effects and support neuron survival.  
 
Significance of the results 
 
Since blocking the α7 signal rescues neurons and blocking all nAChR activity 
exacerbated neuron death, signaling coming through the other nAChR subtype (α3* 
nAChRs) must be involved in neuron survival. Such hypothesis could be used to explain 
the increase in co-localization between the LYPD6B and α3* nAChRs from avian 
embryos kept in constant darkness. The circuitry stimulated by light will release ACh and 
activate the nAChRs located on the ciliary and choroid neurons of the ciliary ganglia. 
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However, in the dark this circuitry remains off, leaving very minimal amounts of ACh 
due to spontaneous activity.  If the signaling from α3* nAChRs is required for the 
support of neuron survival then the neuron would have to adapt a mechanism which 
would allow the α3* receptors to be activated even at low ACh concentrations. Based 
upon the functional data presented in this dissertation, the interaction of LYPD6B and 
α3* nAChRs increases the ACh sensitivity, thus the co-localization of LYPD6B and α3* 
in the dark would be a way to increase the probability of receiving a constant signal 
through the α3* nAChRs.  
 
Though the implications LYPD6B has on programmed cell death were not investigated in 
this dissertation, I am proposing an experiment that will further support such hypothesis. 
A straightforward experiment would be knocking down LYPD6B and through a 
stereology based method count ciliary and choroid neurons from ciliary ganglia of avian 
embryos kept in constant darkness. From this experiment one would expect a decrease in 
cell number for the LYPD6B knockdown group versus the group that still expressed 
LYPD6B.    
 
In order to explore other possible functions of LYPD6B it is pertinent to discuss the 
mechanisms cholinergic neurons use in order to regulate the amount of received nicotinic 
signaling. One mechanism is modifying nAChR response properties by regulating the 
stoichiometry of heteromeric nAChRs. Both the α3β4 and α4β2 heteromeric nAChRs 
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exist in two isoforms: those containing a ratio of 2α:3β or 3α:2β (Moroni and Bermudez, 
2006).  For the α4β2 heteromeric nAChRs the two isoforms differ in their channel 
properties, cation permeability, and response to chronic nicotine. The (α4)2(β2)3 is 
known as the high sensitivity form because it is more sensitive to ACh, whereas the 
(α4)3(β2)2 is known as the low sensitivity form because it is less sensitive to ACh 
(Mazzaferro et al., 2011). By measuring the Ca2+ reversal potential it was determined that 
the low sensitivity (α4)3(β2)2 receptor had a higher permeability to Ca2+ then the high 
sensitivity (α4)2(β2)3 nAChRs (Tapia et al., 2007). Chronic nicotine exposure to α4β2 
nAChR transfected HEK 293 cells portrayed channel properties similar to the low 
sensitivity (α4)2(β2)3 receptor form (Kuryatov et al., 2005; Nelson et al., 2003), 
suggesting that nicotine behaves as an assembly chaperone only for the low sensitivity 
isoform.  
 
Another mechanism in regulating the amount of nicotinic signaling received is increasing 
or decreasing expression of a particular nAChR type. Though increasing or decreasing 
expression of a nAChR may occur at the transcription level a post-translational approach 
is through exocytosis and endocytosis. Exocytosis is the fusion of small vesicles to the 
plasma membrane allowing a variety of proteins to be located in the plasma membrane. 
Endocytosis is the removing of small vesicles from the plasma membrane, thus removing 
where proteins are located (Tojima and Kamiguchi, 2015). The last method is through 
post-translational modifications. Examples of these include palmitylation, myristoylation, 
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glycosylation, and phosphorylation all of which have been known to occur in the α4β2 
and α7 nAChRs (Alexander et al., 2010; Fenster et al., 1999a; Hoffman et al., 1994; 
Kawai and Berg, 2001; Ramarao and Cohen, 1998).   
  
Though data presented in this dissertation demonstrates that LYPD6B modulates the 
response properties of the α3* heteromeric nAChR, it does not exclude the possibility of 
having chaperone protein-like functions. An example of this would be the assembly of a 
particular stoichiometry for heteromeric nAChRs; such example has been seen with 
LYNX1. By conducting a donor-recovery after photobleaching (DRAP) FRET 
experiment on mouse N2a cells transfected with a particular nAChR subunit plus or 
minus LYNX1 it was determined that LYNX1 stabilized the α4/α4 dimer. More 
specifically, cells co-transfected with α4-GFP and α4-mCherry showed an increased in 
FRET efficiency in the presence of LYNX1 (Nichols et al., 2014). However, these 
observations were not observed with cells co-transfected with β2-GFP and β2-mCherry 
(Nichols et al., 2014). These data imply LYNX1 to stabilize the low sensitivity α4β2 
nAChRs that is those that have an α4/α4 interface. Additionally, the ACh EC50 from 
N2a cells transfected with α4-GFP, β2-wt nAChR subunits, and LYNX1-mCherry 




Another chaperone protein-like function is increasing or decreasing the expression of 
nAChRs, in other words the idea that LYPD6B has the ability to traffic nAChRs. Again 
an example of this has been observed for a different prototoxin protein, Ly6h. The 
amount of α7 expressed on the surface of HEKtsa cells, previously transfected with YFP-
α7 cDNA alone or in combination with Ly6h, was quantified via a biotinylation labeling 
method. The cells were labeled with biotin, lysed, biotin was then immunoprecipitated 
with streptavidin, and Western blotted to determine the levels of internal versus surface 
α7 (Puddifoot et al., 2015). The cells that were co-transfected with Ly6h exhibited a 
decrease in surface of α7 expression (Puddifoot et al., 2015), an indication that Ly6h is 
retaining the α7 nAChR.  
 
A provocative idea is the possible function/s prototoxins may have on diseases 
characterized by a nicotinic signaling imbalance, such as Alzheimer’s disease (AD). AD 
is one of the most common causes of dementia (Kumar et al., 2015). Though there are 
two types of AD the more common type is known as sporadic (SAD) (Kumar et al., 
2015). The characteristics of AD include the accumulation of amyloid β (Aβ) plaques 
around neurons and the hyperphosphorylation of microtubules due to the tau protein, 
which leads to the formation of neurofibrillary tangles inside neurons (Kumar et al., 
2015). These events are thought to cause an increase in cholinergic neuron death. As a 
consequence of cholinergic neuron death is a decrease in nicotinic signaling, this 
decrease in nicotinic signaling is thought to be a contributing factor in the cognitive 
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deficits observed in AD patients (Kumar et al., 2015). However, the identification of 
cholinergic neuron death has been done on post-mortem tissue and fails to explain what 
may contribute to cognitive deficits at earlier time points.  
 
I propose that an imbalance in nicotinic signaling, due to deficiencies in prototoxin 
protein expression, may be a cause of the cognitive deficits observed in AD patients. 
Such idea has been explored for the prototoxin LYNX1. An H&E staining on coronal 
sections through the dorsal striatum of the LYNX1 knockout mouse portrayed a 
vacuolating phenotype (Miwa et al., 2006). It was concluded that such vacuolating 
phenotype was due to an increase in neuron death. This conclusion was also supported by 
the mixed cortical cultured neurons, from the LYNX1 knockout mouse, which exhibited 
a decrease in percent neuron survival when exposed to 100µM of glutamate (Miwa et al., 
2006). Additionally, the cortical cultured neurons were not protected by a10µM nicotine 
pre-treatment (Miwa et al., 2006). It was concluded that the absence of LYNX1 increased 
a neurons susceptibility to glutamate excitotoxicity, because of increased nicotinic 
signaling (Miwa et al., 2006). It would be interesting to determine if LYPD6B behaves 
similarly to LYNX1. Based upon the functional data presented in this dissertation, 
LYPD6B decrease the amount of signal coming through the α3* nAChRs, AD patients 
that fail to express or lose the expression of LYPD6B would have a higher signal coming 
through the α3* nAChRs making neurons more susceptible to excitotoxicity.  
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Prototoxins may also have function/s in nicotine dependence, which is attributed by the 
imbalance nicotinic signaling of the reward and aversion pathways. The nicotine reward 
pathway has been identified as dopaminergic neurons located in the ventral tegmentum 
area of the midbrain and project to the nucleus accumbens (Corrigall et al., 1994; 
Corrigall et al., 1992), these dopaminergic neurons are known to express the α4, α6, β2, 
and β3 nAChR subunits (Klink et al., 2001; Zoli et al., 2002). In contrast the aversion 
pathway highly expresses the α3, α5, and β4 nAChR subunits in the medial habenula of 
the diencephalon, and have glutamatergic projects to the interpduncular nucleus (De Biasi 
and Salas, 2008; Girod et al., 2000; Mata et al., 1977; Ren et al., 2011; Sheffield et al., 
2000; Staines et al., 1980; Vincent et al., 1980).  
 
Because of a single nucleotide polymorphism (SNPs) identified in the CHRNA3, 
CHRNA5, and CHRNB4 genes (Wen et al., 2014), there has been a large interest in 
determining the relationship α3, α5, and β4 nAChR subunits have in regards to nicotine 
dependence. The α5 knockout mouse via intracranial self-stimulation continuously 
administered nicotine compared to wild type; this was attributed by the absence of a 
nicotine aversion effect (Fowler et al., 2011). Furthermore, the α5 knockout mouse had 
less of a cFos immunoreactivity staining compared to wild type mice brains, an indication 
of less neuronal activity (Fowler et al., 2011). These data suggest that the incorporation 
of the α5 nAChR subunit leads to the activation of the nicotine aversion pathway. When 
determining how this information relates to the α5 D versus α5 N-variant, comparisons 
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of the physiological properties between the α5 N- variant versus D must be made. The 
incorporation of the α5 D-variant into the (α3β4)2 nAChRs exhibits an increase in 
receptor function (George et al., 2012). Meaning there is a greater amount of current 
flowing through the receptor when activated by ACh (George et al., 2012).  The 
incorporation of the α5 N-variant into the (α3β4)2 nAChRs also increases receptor 
function but is statistically less than what is observed for (α3β4)2α5 D-variant nAChRs 
(George et al., 2012). This decrease in the amount of current flowing through the 
(α3β4)2α5 N-variant nAChRs may fail to activate the nicotine aversion pathway. 
Similarly, LYPD6B is seen to decrease the ACh induced maximum current response of 
the α3β4 heteromeric nAChRs containg an α5 D-variant subunit, such observation may 
be another mechanism in nicotine dependence. The genome wide association study 
(GWAS) identified a SNP in the CHRNA5 gene to be associated with nicotine 
dependence and this may be due to the absence of the aversion pathway. However, the 
SNP fails to explain why adolescents display a blunted withdrawal symptom. It would be 
interesting to investigate the expression of LYPD6B in wild type adolescent mice, and 
determine if the expression of LYPD6B within the medial habenula of wild type 
adolescent mice fails to activate the nicotine aversion pathway similarly to the α5 







The first list of future experiments will further test the conclusion that LYPD6B 
specifically modulates the heteromeric α3* nAChRs. A study to be performed in the 
future would be testing LYPD6B against other heteromeric nAChRs. A common 
heteromeric nAChR highly expressed in the brain and known to exist in two 
stoichiometry subtypes is the α4β2 nAChR (Luetje et al., 1990; Moroni and Bermudez, 
2006). Additionally, because my experiments were intracellular macroscopic recordings 
of Xenopus oocytes co-expressing LYPD6B and α3* heteromeric or LYPD6B and α7 
homomeric nAChRs, it would be pertinent to perform single channel recordings to 
further support the functional characteristics observed by LYPD6B against the α3* 
heteromeric and α7 homoeric nAChR subtypes. 
 
The second set of experiments aims to understand the regulation of LYPD6B expression 
in the avian ciliary ganglion. The data in this dissertation demonstrates LYPD6B mRNA 
levels to increase from avian ciliary ganglion of embryos kept in constant darkness, 
suggesting that LYPD6B expression is dependent on the lack of nAChR activity. 
However, when nAChR activity was blocked with the application of nAChR antagonist 
drugs, LYPD6B expression was not restored. Thus, LYPD6B expression is regulated 
independently of any nAChR activity. Future experiments would aim to determine the 
factor/s that regulate the mRNA LYPD6B expression. Additionally, a pixel intensity 
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comparison from immunoflourescence experiments staining for HA/LYPD6B on neurons 
from dissociated avian ciliary ganglia kept in constant dark versus constant light would 
further support the data demonstrating the increase in LYPD6B expression from avian 
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Neuroblastoma is a pediatric extra-cranial solid tumor that accounts for only 7% of 
malignancies in children less than 15 years of age, but makes up 15% of pediatric 
oncology deaths.  Thus it is an aggressive cancer for which new treatments are badly 
needed. In an effort to identify a drug that targets neuroblastoma, we identified, MG 624, 
a nicotinic acetylcholine receptor (nAChR) antagonist, by testing its efficacy in killing 
that tumor initiating cells (TICs) isolated from the bone marrow of patients with stage IV 
neuroblastoma (unpublished data). We discovered that several different TIC cell lines, 
several neuroblastoma cell lines (SKN-SY5Y; SH-KCN, SH-KCNR, and SH-EP), and 
many primary neuroblastoma tumors showed highly elevated levels of transcripts 
encoding CHRNA5 (α5 nAChR subunit) when compared to normal human sympathetic 
ganglia. There was no detectable expression of the CHRNA3	  (α3)	  and CHRNB4 (β4) 
and no relative difference in CHRNA7 (α7) and CHRNB2 (β2) nAChR transcripts.  In 
contrast, skin-derived neural precursors did not express detectable levels of any nAChR 
subunit transcript. We hypothesize that the α5 subunit contributes to the neuroblastoma 
phenotype, and forms a novel functional nAChR with subunits α7 and β2, and that this 
receptor subtype is the target of the drug MG 624. We have confirmed MG624 to kill 
SH-EP cells with the same concentration dependence as on neuroblastoma TICs. 
However, an MG 624 IC50 shift was not observed from intracellular recordings of 
Xenopus oocytes expressing a variety of (α7β2)2α5 nAChR concatemers. The data 
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presented in this paper suggest α5 nAChR subunit to correlate with neuroblastoma, thus a 




Neuroblastoma is one of the most common childhood extra-cranial solid tumors. It 
accounts for more than 7% of malignancies in patients less than fifteen years of age and 
makes up 15% of oncology deaths (Maris et al., 2007). Neuroblastoma occurs in the 
sympathoadrenal progenitor cells, and tumors are formed in the adrenal medulla, 
sympathetic ganglia, and 65% occur in the abdomen (Maris et al., 2007). Current 
treatments for neuroblastoma include surgery, chemotherapy, radiotherapy, and 
biotherapy, all of which are inefficient, with a less than 50% long term survival in high 
risk cases (Maris et al., 2007). This inefficiency could be due to neuroblastoma stem cells 
that are dormant and are capable of being activated and differentiated into tumor like 
cells. Thus, it is clear that a more specific treatment for neuroblastoma is needed.   
 
One way to study neuroblastoma is through the culturing of tumor-initiating cells (TICs). 
Our collaborators, Drs. David Kaplan and Giselle Sholler, have isolated TICs from bone 
marrow aspirates of stage 4 neuroblastoma patients. TICs have features of neuroblastoma 
stem cells, such as self-renewal and the ability to form metastatic tumors in mice (with 
injecting as little as ten cells) (Hansford et al., 2007). In an effort to identify a more 
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specific drug treatment, Dr. Kaplan has screened multiple drugs on TICs. One drug, MG 
624, which is a nicotinic acetylcholine receptor (nAChR) antagonist, was shown to be the 
most effective in killing TICs (unpublished data). This led to the characterization of 
nAChR expression in TICs. TICs showed an increase in α5 expression levels compared 
to cells from normal non-cancerous pediatric sympathetic ganglia following drug 
administration. Also, there was no detectable expression of the α3 or β4 subunits, and no 
relative difference in α7 and β2 expression levels. 
 
The α5 subunit is known as an accessory subunit. Because the α5 subunit does not have a 
ligand binding site, it cannot form a functional nAChR on its own; It needs to be 
combined with other a subunits and/or with other α and β subunits. We hypothesize that 
the α5 subunit can form a novel functional nAChR with subunits α7 and β2 to contribute 
to the neuroblastoma phenotype, and that this receptor subtype is the target of the drug 
MG 624.  
 
The sensitivity of α7β2α5  nAChRs against MG 624 was tested by intracellular two 
electrode voltage clamp recordings on  Xenopus oocytes expressing a variety of α7β2α5  
nAChR stoichiometries. To ensure the expression of α7β2α5, Xenopus oocytes were 
injected with an α7β2α5  mRNA concatemer. A nAChR concatemer is designed so that 
each subunit is liked together and is translated as a single polypeptide, thus restricting the 
stoichiometry. Cell growth rate was characterized in a stable SH-EP α5 (CHRNA5) 
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knockdown cell line in order to determine if the α5 nAChR subunit contributes to the 
Neuroblastoma tumor phenotype. The α7β2α5  nAChRs did not respond differently to 
MG 624 and the SH-EP CHRNA5 knockdown cell line failed to change in proliferation 
rate. Thus, the α5 nAChR subunit does not seem to directly be involved in the 
neuroblastoma phenotype. However, elevated CHRNA5 mRNA expression in the 
neuroblastoma tumors and cell lines suggest a potential neuroblastoma biomarker.  
 
Material and Methods 
Cloning- Native human subunit protein sequences for α7, β2, and α5 nAChR subunits 
were encoded by nucleotide sequences optimized for expression in vertebrate expression 
systems. In order to express the concatemer as a single polypeptide the Kozac and signal 
peptide sequences were removed from all subunits with the exception of the first subunit. 
Additionally a 40- amino acid sequence that includes the C-terminal tail of the preceding 
subunit and alanine-glycine-serine repeats arranged in order to encode enzyme restriction 
sites are paired in between each subunit. Subunits were interchanged by the digesting 
with the appropriate restriction enzyme. Concatemeric receptors were expressed from the 
pSGEM oocyte high expression vector. 
 
Cell culture- Neuroblastoma cell lines were grown at 37°C in 5% CO2. They were 
maintained in 10% (v/v) fetal bovine serum, 20 U/ml penicillin, 20 mg/ml streptomycin, 
2 mM L-glutamine, and 6 mg/ml glucose in modified L15CO2. 
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RNA extraction and qPCR- RNA was extracted from confluent cells using the TRI 
reagent/ chloroform method. qPCR primers were designed using MacVector against the 
CHRNA5 sequence obtained from http://www.ensembl.org/index.html. CHRNA5 
expression levels were determined using the syber green based method.  
 
Transfections- SH-EP cells were transfected using JetPEI (polyplus transfection, Illkirch, 
France). Transfected SH-EP cells were selected with G418 (Sigma, St. Louis, MO, USA) 
at 500 mg/ml.  
 
 In-vitro transcription- 2 µg of nAChR concatemers DNA was linearized with the 
enzyme EcoR1. In-vitro transcription was performed with the enzyme T7 RNA 
polymerase using the kit  MegaScript from Ambion. RNA was purified through the 
MegaClear kit from Ambion.  
 
Electrophysiological Recordings and analysis- Xenopus oocytes were purchased and 
harvested through EcoCyte Bioscience (ecocyte-us.com) and two-electrode voltage-
clamp recording was performed as described in (Boorman et al., 2000). 70 ng of cRNA 
was injected into oocytes with a 50:1 molar ratio RIC3:concatemer. Recording was done 
at -70 mV in OR2 solution (115 mM NaCl, 2 mM CaCl2, and 2 mM KCl) in the presence 
of 1.5 mM atropine. Drug application was perfused for 5 secs then washed for 30 secs. 15 




To confirm if CHRNA5 mRNA levels are elevated in neuroblastoma cell lines, I 
performed quantitative PCR on a sample of tumor initiating cells (TICs), sy5y 
neuroblastoma cell line, SH-EP neuroblastoma cell line, and a skin progenitors (SKPs) 
sample as a control. The CHRNA5 mRNA levels were elevated in the TIC sample, sy5y, 
and SH-EP neuroblastoma cell line compared to SKPs (Fig.1 A). Though the SH-EP 
neuroblastoma cell line showed the smallest increase in CHRNA5 mRNA expression it 
still was elevated when compared to the control group (SKPs). For this reason an MG 
624 growth assay against SH-EP cells was performed. First a MG 624 dose response 
curve against SH-EP cells was performed via a calcein AM assay. The EC50 for MG 624 
against SH-EP cells was determined to be 5 µM (Fig. 1 B). SH-EP cells were then 
incubated for four days with a daily application of 5 µM MG 624. About 50% of plated 
SH-EP cells were viable at two days post MG 624 exposure (Fig. 1 C).  
 
Because SH-EP cells were affected by MG 624 exposure I performed a knockdown by 
transfecting cultured SH-EP cells with four different shRNAs against CHRNA5. The four 
shRNA plasmids tested were noted as 1253, 904, 873, and a negative control (CHRNA5 
scramble). An inital quantitative PCR on transfected SH-EP cells was done to determine 
if there was a knockdown (Fig. 2 A). The most effective shRNA in knocking down 
CHRNA5 was 1253 (Fig. 2 B). The knockdown was about 70% compared to SH-EP cells 
not transfected (Fig. 2 B). 
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A stable CHRNA5 knockdown SH-EP cell line was established by the 1253 shRNA. A 
calcein AM assay was performed against the stable CHRNA5 knockdown SH-EP cell 
line (1253), transfected SH-EP cells with negative shRNA control (NC), and SH-EP cells 
not transfected. The growth of all three-cell lines was measured over three days. There 
was no significant difference in relative fluorescence, thus no difference in viable cells 
among the three cell lines tested (Fig. 3 A). We then went on to determine if the stable 
CHRNA5 knockdown SH-EP cell line was insensitive to MG 624. The 1253, NC, and 
untransfected SH-EP cell lines were comparably sensitive to MG 624 (Fig. 3 B). No 
change in MG 624 sensitivity suggests MG 624 to act on another source besides a 
nAChR. Therefore, we performed another calcein AM assay against all three cell lines 
exposed to methyllycaconitine (MLA). All three-cell lines (1253, NC, and untransfected 
SH-EP cells) are not affected by MLA (Fig. 3 C). Additionally, the sensitivity SH-EP 
cells exhibit against MG 624 further supported the idea that a nAChR is the target of MG 
624. Therefore, I performed intracellular voltage clamp recordings on Xenopus oocytes 
expressing a variety of α7β2α5 nAChRs to determine if there is a shift in the MG 624 
IC50. All α7β2α5 nAChRs tested responded to MG 624, comparably (Fig. 4 A).      
 
Discussion 
The mRNA expression of CHRNA5 in neuroblastoma TICs and cell lines resemble the 
expression identified in other neuron types. Neural crest cells are destined to be 
sympathetic ganglia, the neuroblastoma progenitors, and it was determined that cultured 
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quail neural crest cells express CHRNA5, CHRNA3, and CHRNB4 for 12 days (Howard 
et al., 1995). Additionally, the developing chicken ciliary ganglion has a 400 fold mRNA 
increase in CHRNA5 from embryonic day 8 to 18, a greater increase than the CHRNA3, 
CHRNB4, and CHRNA7 transcripts (Corriveau and Berg, 1993). The sympathetic 
ganglion also expresses the CHRNA5, CHRNA3, CHRNB4, and CHRNA7 transcripts 
(Gardette et al., 1991). However, in these studies the expression of CHRNA5 is 
accompanied by the expression of CHRNA3, CHRNB4, CHRNB2, and CHRNA7.  An 
interesting observation in this study is the absence of CHRNA3 and CHRNB4 mRNA 
expression.   
 
Because the α5 nAChR subunit is known as the “accessory subunit”, its functions are 
related to the modulation of nAChR signaling. The autonomic ganglion expresses the 
CHRNA5, CHRAN3, and CHRNB4 nAChR subunit transcripts and are known to be 
involved in fast EPSPs (Rassadi et al., 2005; Ullian et al., 1997). The CHRNA5 
Knockout mouse exhibits increase nicotine consumption, due to the decrease in 
cholinergic neuron activity within the medial habenula (Fowler et al., 2011). Though 
these studies identify the α5 nAChR subunit to directly affect the cholinergic signaling, 
there are no studies that investigate the developmental function of the α5 nAChR subunit.  
 
Though this paper determined CHRNA5 to not have a direct role in the neuroblastoma 
phenotype it does not discard the importance the α5 nAChR subunit may have in 
neuroblastoma. All of the TICs, neuroblastoma cell lines, and primary tumors express 
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elevated CHRNA5 mRNA levels. However, knocking down CHRNA5 did not alter the 
SH-EP phenotype. Thus, CHRNA5 is not directly involved in the neuroblastoma 
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Table 1. All α7β2α5  nAChR subtypes respond to MG 624 similarly. There is no 
significant change in the MG 624 LogIC50 and Hill slope for all of the different for 
























nAChR type LogIC50 Hill Slope 
α7α7α7α7α7 -6.2 -0.94 
α7α7α5β2α7 -6.0 -0.62 
α7β2α5β2α7 -6.6 -0.80 
α7β2α5α7α7 -6.6 -0.80 
α7α7α5α7α7 -6.3 -0.64 
α7β2α7β2α7 -6.3 -0.81 
α7β2α7α7α7 -6.2 -0.80 
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Figure 1. Determining CHRNA5 levels in neuroblastoma cell lines and testing MG 
624 efficacy. A. CHRNA5 transcript levels are elevated in neuroblastoma TICs and cell 
lines. B. A calcein AM assay determined viable SH-EP cells based off of relative 
fluorescence. The EC50 for MG 624 against SH-EP cells is 5 µM. C. Four day 5 mM 
MG 624 exposure on SH-EP cells versus DMSO exposure. At two days of MG 624 
exposure 50% of the cells were viable. MG 624 treated cells are closed circles and 
DMSO treated cells are open circles. 
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Figure 2. Quantitative PCR on shRNA transfected SH-EP cells. A. All shRNA 
transfections knocked down the CHRNA5 transcript. B. The 1253/shRNA was the most 
effective in knocking down the CHRNA5 transcript, with a 70% knockdown. 
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Figure 3. CHRNA5 knockdown in SH-EP cells did not affect proliferation rate, MG 
624 or MLA. A. 1253/shRNA SH-EP cell line to proliferate at a comparable rate to the 
negative control and untransfected SH-EP cells. B. 1253/shRNA SH-EP cell line MG 624 
sensitivity is comparable to the negative control and untransfected SH-EP cells. C. MLA 





Figure 4. The LogIC50 did not shift for the different α7β2α5  nAChR 
stoichiometries. A. MG 624 dose response curves for α7β2α5 nAChRs.  
 
 
 
 
 
